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ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is growing in prevalence across the
world and is associated with a significant economic cost. In addition to life style
modification, no pharmacotherapy method is available to treat NAFLD.

As the

histology of the liver changes over the course of the disease, it can be expected that the
liver proteome will change too. Included in the liver proteome are drug disposition
proteins comprised of drug metabolizing enzymes and transporters. These proteins are
responsible for the removal of drugs and endogenous compounds from the body. The
goals of this dissertation were:

(1) Develop methodology to accurately and

reproducibly measure drug metabolizing enzymes and transporters and (2) determine
the alterations in these proteins as a result of the progression of NAFLD and diabetes.
Manuscripts I and II are used to develop the methodology required to measure the
proteins of interest and determine other variables that may be affecting protein
expression changes besides disease. Manuscripts III and IV bring biological effect
into the equation to determine how NAFLD and diabetes change the proteome and
compare the results to a mouse model of NASH to assess its validity. The manuscripts
are briefly described below:
Manuscript I: Hepatic xenobiotic transporters in the human liver play an important
role in the elimination of drugs or toxins and significantly contribute to variability in
drug response. We have developed a label-free mass spectrometry-based method to
study the protein expression of 13 of 25 clinically relevant transporter proteins (6 ABC
and 7 SLC) in liver tissue from 20 donors (9 female, 11 male).

Whole tissue

homogenate was used, and in-solution trypsin digestion was performed using pressure-

cycling technology. Data was acquired in data-dependent and sequential window
acquisition of all theoretical mass spectra (SWATH-MS) mode. Bovine serum
albumin (BSA) was spiked in each sample before digestion and monitored for batch to
batch variability. Spectronaut™ was used for peptide identification and data
extraction from SWATH files. Na+/K+ transporting subunit alpha 1 (ATP1A1), was
quantified as a cell membrane marker and its coefficient of variation was 16.6% across
different liver samples. The work highlights the suitability of SWATH-MS for largescale simultaneous quantification of several xenobiotic transporters important in drug
disposition. We found that average differential expression of transporters proteins was
similar and much smaller than the inter-individual variability observed between the
genders.
Manuscript II: Human liver tissue utilized in drug metabolism (DM) studies is
retrieved from brain-dead individuals receiving an array of therapeutic agents during
hospitalization. The anticonvulsant agent phenytoin, a potent cytochrome P450 (CYP)
3A4 inducer, is among such agents that potentially can impact the expression and
activity of DM enzymes. Here we identify and highlight the need to screen human
liver tissues for the presence of phenytoin. One-hundred and six samples from an inhouse repository of human livers were screened for the presence of phenytoin and
1,702 other compounds utilizing AB SCIEX forensic library and a Triple TOFinstrument. Phenytoin concentration were then quantified in phenytoin positive tissue
using LC-MS/MS. Activity levels for CYP3A4 were collected in-house as well as
provided by the vendor. Expression of CYP proteins were analyzed by an untargeted
proteomic analysis. mRNA levels for all CYPs and certain nuclear transcription

factors were also measured. Non-parametric independent sample tests were run in
SPSS and comparisons with a p-value <0.05 were considered significant. Phenytoin
was present in 34 of the 106 human livers (32%) and the functional activity and
protein level of CYP3A4 were significantly higher in these samples. Caution should
be taken when performing studies with commercially available liver sample and
microsomes prepared thereof. The use of ambiguous protein expression values due to
induction from phenytoin may decrease the accuracy of PBPK models developed
using such data.

Whenever possible, we suggest that livers tissue, primary

hepatocytes and liver microsomes be screened for phenytoin to prevent altered results
due to the induction of DMEs.
Manuscript III: Differential basal expression of drug metabolizing enzymes (DMEs)
and transporters in disease state can contribute to significant changes in systemic
exposure of xenobiotics. To gain insight into the alterations of these proteins during
non-alcoholic fatty liver disease (NAFLD) and diabetes, we investigated the protein
abundance and activity in 106 human liver samples. In-solution trypsin digestion of
proteins in whole tissue lysate was carried out using pressure-cycling technology. Data
were acquired in data-dependent acquisition (DDA) and sequential window
acquisition of all theoretical ion mass spectra (SWATH-MS) mode on a time of flight
(TOF) mass spectrometer, and absolute protein levels were determined using total
protein approach. Functional activity data from the tissue vendor were used to evaluate
the effect of disease on cytochrome P450 (CYP450) activity and further correlated
with protein abundance. It was found that NAFLD altered CYP20A1, CYP27A1,
CYP2B6, CYP2E1, CYP3A4, CYP2J2, UGT1A3, UGT1A4, SULT2A1, BSEP and

MRP2 protein expression.

Diabetes was found to significantly alter the protein

expression of CYP4F11, CYP20A1, CYP27A1, CYP2B6, CYP2E1, CYP3A4,
CYP2J2, SULT1B1, SULT1A1, UGT1A3, UGT1A4, OATP1B3 and OATP2B1. It is
important to point out that when livers containing the anticonvulsant, phenytoin, were
excluded from the analysis, the changes seen in CYP3A4 were no longer significant.
In some cases, both diseases altered the expression of the same protein leading to
potentially exacerbated implications. It is important to study these special populations
as patients with NAFLD and diabetes tend to be prescribed more medications than
healthy individuals. The alteration to drug disposition proteins could lead to an altered
pharmacokinetic profile and sub therapeutic or even toxic results.
Manuscript IV: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent
disease in our modern society. It is important to develop an accurate mouse model
that is representative of the disease. The American Lifestyle Induced Obesity
Syndrome (ALIOS) model aims to cause mice to develop NAFLD through diet and
lifestyle management simulating western culture. Determining the proteomic changes
occurring to the drug metabolizing profile is critical to assess if the model accurately
translates to humans. Pressure-cycling technology aided trypsin digestion was carried
out on the whole tissue lysate from human and mouse livers. Both a data-dependent
and data-independent acquisition method was used to acquire data on a time of flight
(TOF) mass spectrometer. Absolute protein quantification was determined and fold
change analysis in each species was performed between the healthy and disease state.
It was found that about 75% of cytochrome P450s (CYPs) related to xenobiotic
metabolism showed the same change from mouse to humans. Phase II metabolic

enzymes were accurate 50% of the time and transporter differences were accurate in
the two proteins that were measured. The enzymes that did not properly match up
were mainly proteins that had poor orthology between the species.
Conclusions: The ALIOS model looks to be an accurate representation for the
majority of drug metabolism related CYPs.
Conclusion: This work demonstrates the hepatic proteomic changes that occur as
NAFLD and diabetes progress. Numerous drug disposition proteins are altered in both
disease states with some overlap. This indicates that diabetes can exacerbate the
changes seen in NAFLD. These changes can result in altered metabolic profiles and
allow for a better understanding of how to better treat individuals with NAFLD.
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PREFACE
This dissertation has been written in manuscript style format. The first chapter
is a basic background and introduction to NAFLD and proteomics. Chapters 2-5 are
the manuscripts. Manuscript I entitled, “SWATH-MS Based Method for
Simultaneous Absolute Quantification of 13 Clinically Important Drug Transporters in
Human Liver” is relatively simple method for measuring the absolute protein
expression of certain clinically relevant drug transporters and demonstrates the
differences that arise due to gender. Manuscript II, entitled “Presence of Drug
Metabolizing Enzymes Inducers in Commercially Available Human Liver Samples
Results in Altered Metabolic Profiles” is about to be submitted for review in Drug
Metabolism and Disposition. It shows the importance of screening human liver
samples for medications prior to performing enzyme studies due to the potential for
altered metabolic profiles. Manuscript III, entitled “Non-Alcoholic Fatty Liver
Disease (NAFLD) and Diabetes – Effect on the Protein Abundance and Activity of
Human Hepatic Drug Metabolizing Enzymes and Transporters” demonstrates the
effect that nonalcoholic fatty liver disease has on multiple phase I and phase II drug
metabolizing enzymes and xenobiotic transporters. Manuscript IV, entitled
“Evaluation of The American Lifestyle Induced Obesity Syndrome (ALIOS) Mouse as
a Model for Human Drug Metabolizing Enzymes Using SWATH-MS Proteomics”
compares the drug metabolizing proteome of human livers that are affected by NASH
to a mouse model that induces NASH by diet modification. All manuscripts have my
major professor, Dr. Fatemeh Akhlaghi, as the corresponding author.

All other

contributors have been acknowledged appropriately and included as co-authors.
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BACKGROUND
Introduction
Nonalcoholic fatty liver disease (NAFLD), a chronic liver condition that is
increasing in prevalence around the world, can range from reversible simple steatosis,
to irreversible and life-threatening cirrhosis and liver cancer. Along with lifestyle
management, patients with NAFLD are generally prescribed numerous medications to
treat their metabolic syndrome. These drugs must be cleared from the body and the
liver, the main site for drug metabolism, contains drug metabolizing enzymes and
transporters that facilitate the elimination of many compounds and their ultimate
removal from the body. Any change to these proteins can result in altered exposure to
systemic circulation and effects on a target. Considering the human liver tissues that
are used in research come from donors who were hospitalized prior to death, it is also
important to determine if they were receiving medications that may induce or inhibit
drug metabolism. Alterations to these important proteins can cause changes to a
person’s pharmacokinetic and pharmacodynamic profile but it is also imperative to
make sure these changes are not a result of an exogenous compound rather than
NAFLD itself.
Nonalcoholic fatty liver disease (NAFLD) is a growing concern around the world.
In the United States alone, prevalence of NAFLD has been found to be 30% with
10.3% of these patients having advanced fibrosis 1. It is estimated that over 64 million
people in the US have NAFLD and this is associated with a significant economic
burden of approximately $103 billion or about $1,600 per patient 2. NAFLD is defined
by the presence of >5% macrovascular steatosis without high alcohol intake. There
1

are multiple stages of NAFLD starting with benign fatty liver which can lead to
nonalcoholic steatohepatitis (NASH) and even liver cancer or cirrhosis 3. Hepatocyte
ballooning, fibrosis and lobular inflammation along with steatosis are associated with
the later stages of this disease 4. This disease is also commonly associated with insulin
resistance, obesity, cardiovascular diseases, lipotoxicity and hepatic fat accumulation5.
Currently, there is a lack of consensus and little information regarding the effect of
NAFLD on important drug metabolizing enzymes (DMEs) and transporters found in
the liver 6. Of the few studies on DMEs in humans with NAFLD, it has been found
that significant downregulation of CYP3A4 and CYP1A2 occurs in the progression of
the disease

7,8

. DMEs and transporters in the liver are responsible for the elimination

of both exogenous and endogenous compounds found in the body. Specifically, the
cytochrome P450 (CYP) family of enzymes are responsible for 70-80% of the
metabolism of currently marketed drugs 9. Drug transporters are responsible for the
active transport of drugs into and out of cells that would not normally move across
passively

10

. Together, these proteins are moderators of the absorption, distribution,

metabolism and elimination (ADME) of compounds both foreign and endogenous to
the human body.
Certain commonly prescribed drugs can be classified as either inducers of
inhibitors of CYPs which can affect their ability to metabolize drugs. CYPs have the
ability to metabolize multiple drugs so whenever two drugs are given concurrently,
interactions can possibly exist 11. Inhibition can occur as either irreversible inhibition,
reversible inhibition or quasi-irreversible inhibition

11

. Induction can occur when a

drug has an activation effect on nuclear receptors responsible for regulating the

2

production of certain CYPs. For example, phenobarbital activates the nuclear receptor
CAR which then upregulates CYP2B, CYP3A and CYP2C family of enzymes

12

.

Transporters are also known to be induced by some xenobiotics. P-glycoprotein (Pgp), along with CYP3A4, was found to be significantly induced by rifampin

13

.

Similarly, efavirenz, an HIV-1 drug, was found to induce the expression of both P-gp
and CYP3A4

14,15

. It is important to perform a thorough screening of donor liver

tissues prior to metabolic and proteomic studies as inducers and inhibitors could affect
results. For example, dexamethasone, a known weak inducer of CYP3A4 16, is used at
a concentration of 16 mg/L in University of Wisconsin (UW) solution when
preserving tissue

17

. Additionally, methylprednisolone, a CYP2C8 inhibitor, may be

administered to patients after brain death to stabilize lung function

18,19

. The use of

dexamethasone or methylprednisolone could result in alteration to CYP metabolism
which in turn would show false activity and proteomic data, possibly resulting in the
masking of the true effect of NAFLD. It is important to discover the true effect of
NAFLD on drug metabolism in order to discover new treatment and early detection
methods.

Significance of This Work
The manuscripts in this dissertation are centered around the continued exploration
of the effect that NAFLD has on the human liver and other factors that may be
masking its true effect. The significance of this research is listed below.

3

1. Certain medications can remain in the liver after donation.

These

compounds have the potential to induce or inhibit certain drug
metabolizing enzymes.
2. Drug transporters are a large part of the metabolic profile and effectiveness
of many drugs. Historically, they have been difficult to measure, and new
methods need to be discovered to make their measurement a simpler
process.
3. Current research in the effect of Non-Alcoholic Fatty Liver Disease on
drug metabolizing enzymes and transporters is currently sparse and
variable. It is imperative to better understand the effect this disease is
having on a significant portion of the population in order to better treat
patients with the disease itself or a combination of other diseases.

Objectives of the Research
The overall objective of this dissertation was to develop new methodology for the
measurement of drug metabolizing enzymes and low abundance drug transporters in
order to determine the effect that NAFLD has on them. Additionally, as a donor
medication list is not provided when obtaining human liver samples, it was important
to determine what small molecules were remaining and the effect these drugs were
having on certain protein, enzymatic and mRNA studies. In this regard, each
manuscript has its own specific objectives:

4

1. “SWATH-MS based method for simultaneous absolute quantification of 13
clinically important drug transporters in human liver”:
a. Develop a simple method of the quantification of drug transporters in
healthy human liver samples.
b. Evaluate the accuracy of the measurements when compared to literature
values using complex methodology.
c. Determine if there was an effect on transporter expression levels due to
gender differences.

2. “Presence of Drug Metabolizing Enzymes Inducers in Commercially Available
Human Liver Samples Results in Altered Metabolic Profiles”
a. Create a method to successfully screening human liver samples against
a known forensic compound identification library.
b. Determine if any compounds identified were ones that are known to
cause induction or inhibition of drug metabolism.
c. Evaluate the effect that the found inducers or inhibitors were having on
the enzymatic activity, protein expression and mRNA expression of
specific DMEs.
d. Evaluate the changes observed using a PBPK model to simulate the
effect being seen.

5

3.

“Non-alcoholic fatty liver disease (NAFLD) and diabetes – Effect on the
protein abundance and activity of hepatic drug metabolizing enzymes in
human”
a. Measure protein expression levels for a wide variety of phase I and
phase II drug metabolizing enzymes and drug transporters.
b. Determine the effect that different stages of NAFLD were having on
the specific protein levels.

4. “Evaluation of The American Lifestyle Induced Obesity Syndrome (Alios)
Mouse as a Model for Human Drug Metabolizing Enzymes Using SWATHMS Proteomics”
a. Measure protein expression levels of phase I and phase II drug
metabolizing enzymes and drug transporters in human and mouse
livers.
b. Compare the expression level between healthy livers and those with
nonalcoholic steatohepatitis (NASH).
c. Determine if the changes are similar between mouse and human liver
samples.

Organization of Dissertation
The remainder of this dissertation will be organized as follows:
Manuscript 1 describes the work in the manuscript “SWATH-MS based method
for simultaneous relative quantification of 13 clinically important drug transporters in
human liver,” which provides novel methodology used for the rest of the experiments
6

throughout the other Manuscripts.

This work involved the development of new

protein digestion and mass spectrometry analytical methods in order to accurately
quantify drug metabolizing enzymes and transporters in a single sample.

The

Manuscript additionally compared certain quantified transporters to reported literature
values and does a general comparison to discover gender differences.
Manuscript 2 describes the work related to the manuscript, “Presence of Drug
Metabolizing Enzymes Inducers in Commercially Available Human Liver Samples
Results in Altered Metabolic Profiles,” which involves the screening of human liver
samples for drugs or medications present. It also describes the further investigation of
the drug, phenytoin, and the affect seen in the alteration of drug metabolizing enzymes
due to the induction potential of phenytoin.
Manuscript 3 describes the work related to the manuscript, “Non-alcoholic fatty
liver disease (NAFLD) and diabetes – Effect on the protein abundance and activity of
hepatic drug metabolizing enzymes in human,” which involves the analysis of phase I
and II drug metabolizing enzymes and xenobiotic transporters and the affect seen due
to nonalcoholic fatty liver disease.
Manuscript 4 describes the work related to the manuscript, “Working Title,” which
involves the comparison in proteomic changes of drug metabolizing enzymes and
transporters in human livers and the American Lifestyle Induced Obesity Syndrome
mouse model.
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1.1 Abstract
Hepatic xenobiotic transporters in the human liver play an important role in the
elimination of drugs or toxins and significantly contribute to variability in drug
response. We developed a label-free mass spectrometry-based method to study the
protein expression of 13 of 25 clinically relevant transporter proteins (6 ABC and 7
SLC) in liver tissue from 20 donors (9 female, 11 male). Whole tissue homogenate
and in-solution trypsin digestion was performed using pressure-cycling technology.
Data was acquired in data-dependent and sequential window acquisition of all
theoretical mass spectra (SWATH-MS) mode. Chromatographic separation was
achieved over a 180-min gradient on Acquity UPLC BEH C18 peptide column, and
mass spectrometer was operated in positive ionization mode. Bovine serum albumin
(BSA) was spiked in each sample before digestion and monitored for batch to batch
variability. Spectronaut™ was used for peptide identification and data extraction from
DDA and SWATH-MS files. Na+/K+ transporting subunit alpha 1 (ATP1A1), was
quantified as a cell membrane marker and its coefficient of variation was 16.6% across
different liver samples.
Significance: The work highlights the suitability of SWATH-MS for large-scale
simultaneous quantification of several xenobiotic transporters important in drug
disposition. We found that average differential expression of transporters proteins was
similar and much smaller than the inter-individual variability observed between the
genders.
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1.2 Introduction
Xenobiotic transporters play a crucial role in drug disposition by mediating
drug uptake and efflux. These proteins govern the absorption, distribution,
metabolism, and elimination of drugs, toxins and endogenous molecules across the
cell membrane. Thus, transporters can govern the rate-limiting step in systemic and
tissue exposure of drugs. Biologically, transporters are membrane-bound proteins are
ubiquitously expressed throughout the body. These proteins are mostly localized on
the apical or basolateral membranes of various organs including intestine, liver,
kidney, and brain and facilitate the efflux and uptake of xenobiotics 1. The ATPbinding cassette (ABC) family and the solute carrier (SLC) family represent the two
significant superfamilies of membrane transporters in humans

2-4

. ABC transporters

utilize ATP for transport of substrates across the membrane, and most efflux
transporters belong to this family. In contrast, SLC transporters mainly facilitate
uptake can be active or facilitated. Some SLC transporters also mediate bidirectional
movement of molecules. Altered systemic exposure and organ toxicity can be related
to transporters mediated drug interactions

1,5

. Therefore, the last decade has seen a

significant amount of research focusing on quantification and deorphanization of these
transporters as well as elucidation of their functionality 6,7. Inter-individual variability
in the expression and drug response of xenobiotic transporters may arise from nongenetic (age and gender), genetic (polymorphism), and regulatory factors 8. While
more than 400 different transporters have been annotated in the human genome, the
function of many of these remains unknown 2,9.
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Efflux transporters localized on the canalicular membrane (e.g., P-gp/MDR1,
MRP2, BCRP, BSEP, MDR3, and MATE1) facilitate excretion of molecules from
hepatocytes into bile

4,6,10

. Meanwhile, basolateral hepatic efflux transporters (e.g.,

MRP1, MRP3, MRP4, MRP5, and MRP6) return molecules to hepatic blood from the
hepatocyte

4,6,11

. Prominent uptake transporters that are localized on the sinusoidal

membrane of hepatocytes include NTCP, OATP1B1, OATP1B3, OATP2B1, OAT2,
and OCT1

12,13

. These uptake transporters facilitate uptake of drugs from the blood

into the hepatocyte thereby facilitating metabolic clearance of drugs.

Moreover,

OAT7 on the sinusoidal membrane and sterolin-1 and sterolin-2 on basolateral
membrane mediate bidirectional (efflux and uptake) transport of various substrates
14,15

.
Traditionally, researchers have relied on quantification of mRNA expression of

transporters as a surrogate to the functional activity in the tissue. However, a weak
correlation was observed between mRNA and protein expression in human livers 16,17.
Protein abundance levels of these transporters are usually estimated by cumbersome
Western blot analyses that is semi-quantitative at best. Last decade has seen a rise in
the use of mass-spectrometry (MS) based techniques for quantification of the protein
expression

10,18

. Available MS methods for quantification of liver transporters are

based on targeted quantitative proteomics approaches

10,16,17,19,20

. A comprehensive

cost comparison of different mass spectrometry-based techniques reported significant
cost savings with label-free based quantitative (LFQ) proteomics 21. LFQ approaches
are relatively inexpensive as compared to targeted MRM methods as there is no need
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to synthesize unique peptides for each protein and isotopically labeled isoforms of
these peptide as the internal standard.
LFQ using the sequential window acquisition of all theoretical ion mass
spectra (SWATH-MS) technique provides an alternative to the targeted approaches for
protein quantification

22

. SWATH-MS is a data-independent acquisition (DIA)

technique in which all the precursors within a predefined m/z are fragmented, and
product ions of these precursors are recorded as a digital repository

23

. The data are

further deconvoluted and extracted using software like OpenSWATH, SWATH 2.0,
Spectronaut and Skyline

24,25

. A significant advantage of SWATH-MS over the other

mass spectrometry methods is related to the ability to perform retrospective mining of
the data. For instance, if the researcher comes up with a new hypothesis in the future,
SWATH-MS data would allow interrogation of the existing data for additional
protein/s of interest without the need for addition sample digestion or data
reacquisition. Such a strategy offers a tremendous benefit concerning saving of
sample, time and money. A high linear association between MRM based methods with
SWATH-MS has been shown in the past making it a suitable and reliable technique
for proteomics-based studies

26,27

. Nakamura et al. also described a SWATH-MS for

quantification of drug-related transporter proteins in human liver microsomes,
however no gender specific differences were reported due to use of small sample size
(n=4) [25].
In this work, we report the development of a SWATH-MS based method to
study the gender-specific differential expression of important drug and xenobiotic
transporters in human liver (6 ABC and 7 SLC family). The transporter proteins were
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shortlisted based on the recommendation made by the International Transporter
Consortium (ITC), the US Food and Drug Administration (USFDA) and the European
Medicines Agency (EMA), as human xenobiotic transporters that play a significant
role in drug discovery 6,7,28.
1.2 Materials and methods
1.2.1 Chemicals and reagents
Protein preparation kit, TPCK-treated trypsin, and MS tuning solution was
obtained from SCIEX (Framingham, MA).

Acquity UPLC Peptide BEH C18

analytical column and VanGuard pre-columns were procured from Waters Corp.
(Waltham, MA). 1,4-Dithiothreitol (DTT) was obtained from Roche Diagnostics
(Indianapolis, IN). Sodium deoxycholate and iodoacetamide (IAA) were procured
from Sigma Aldrich (St. Louis, MO). MS grade acetonitrile, bovine serum albumin
(BSA) and formic acid were purchased from ThermoFisher (Waltham, MA).
1.2.2 Human liver bank
Frozen human liver samples from brain dead donors were purchased from
Sekisui XenoTech LLC, Kansas City, KS. All the livers are from organ donors
involved in automobile accidents and therefore are IRB-exempt. All livers were from
non-diabetics and did not have any stage of non-alcoholic fatty liver disease. The age
of liver donors ranged from 21 to 73 years, with 11 males and 9 females. The detailed
demographics of the donors is given in Table 1.1.
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1.2.3 Human liver tissue preparation
Liver tissue (~50 mg) was homogenized using a bead homogenizer (Omni
Bead Ruptor, Kennesaw GA) in 1000 µl of homogenization buffer (8 M Urea, 50 mM
Triethylammonium Bicarbonate (TEAB), 10 mM DTT w/v)

29

. Samples were then

spun at 1,000 g for 5 min. Supernatant was collected and Pierce BCA protein assay
kit (ThermoFisher Scientific, Waltham, MA) was use used to estimate protein
concentration.
1.2.4 Pressure-cycling technology (PCT) aided trypsin digestion
Protein digestion was performed as previously described with modifications
29,30

. Homogenate samples (250 µg) were spiked with 2 µg undigested bovine serum

albumin (BSA). Samples were denatured with 25 µL DTT (100mM) at 35˚C for 30
min at 120 rpm followed by alkylation in the dark with 25 µL IAA (200 mM) for 30
min at room temperature.

Protein was then concentrated using ice cold water,

methanol and chloroform (1:2:1) followed by centrifugation at 10,000 rpm for 5 min
at 10˚C. The resulting pellet was washed with ice cold methanol and resuspended in
100 µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v sodium
deoxycholate (DOC). TPCK-treated trypsin (12.5 µg) was then added at a ratio of 1:20
(trypsin:protein) and transferred into digestion tubes (PCT MicroTubes, Pressure
Biosciences Inc., Easton, MA). The barocycler was run for 75 cycles at 35˚C with 60
sec pressure cycles (50 sec at 25 kpsi, 10 sec at ambient pressure). Samples were
removed, the same amount of trypsin was added and the barocycler was run again as
above.

After digestion, 110 µL of digested peptides were added to 10 µL

acetonitrile/water (1:1 v/v, containing 5% formic acid) to precipitate DOC and stop the
17

trypsin digestion. Samples were centrifuged for 5 min at 10,000 g and 10˚C to pellet
the DOC. One hundred microliters of the supernatant were reserved for LC-MS/MS
analysis. Subsequently, 25 µL of the digested peptides were injected onto the
analytical column and used for the LC-MS/MS method described below.
1.2.5 LC-MS/MS Analysis
Mass spectrometry analysis was performed as described previously with
modifications

31

. All experiments were performed on a SCIEX 5600 TripleTOF®

mass spectrometer equipped with a DuoSpray™ ion source (SCIEX, Concord,
Canada) coupled to Acquity UHPLC HClass system (Waters Corp., Milford, MA,
USA). Sample separation was achieved on an Acquity UPLC Peptide BEH C18 (2.1 X
150 mm2, 300 Å, 1.7 µm) attached to an Acquity VanGuard pre-column (2.1 X 5 mm2,
300 Å, 1.7 µm). Autosampler and analytical column were maintained at 10°C and
50°C, respectively. The chromatographic separation was achieved over a 180-min
gradient at 100 μL/min. A linear gradient was used for chromatographic separation
using mobile phase A (Water, 0.1% formic acid) and mobile phase B (Acetonitrile,
0.1% formic acid). The solvent composition was 98% A from 0 to 5 min, 98% to 70%
A from 5 to 155 min, 70% to 50% A from 155 to 160 min, 50% to 5% from 160 to
170 min, 5% A held from 170 to 175 min. The gradient was held at initial conditions
from 175 min until the end of the run to equilibrate the column before the start of next
run. Mass calibration of the TOF detector was monitored by injecting trypsin-digested
β- galactosidase peptides every 12 hours during the analysis.
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1.2.6 Data-dependent and SWATH-MS acquisition parameters
Data-dependent, as well as data independent (SWATH) analysis, was
performed in positive ionization mode. The method specific parameters were as
follows: gas 1 (GS1) 55 psi, gas 2 (GS2) 60 psi, curtain gas (CUR) 25 psi. The
source-specific parameters were as follows: temperature (TEM) 450°C, ion spray
voltage floating (ISVF) 5500 V, declustering potential (DP): 100, collision energy
(CE) 10, collision energy spread (CES) 15.
A maximum of 50 candidate ions with a charge state 2 to 4 was monitored
every survey scan cycle. All the ions between m/z 300-1250 which exceeded 25 cps
were subjected to MS/MS analysis. Rolling collision energy dependent on the m/z of
the ion and dynamic accumulation were used. The mass tolerance was set at 50 mDa
during the initial 0.75 sec survey scan (total cycle time: 3.50 sec).
All the parameters for SWATH acquisition were similar as described above
except the following: TOF masses were collected from m/z 300 to 1500 and SWATH
data was acquired (m/z 400-1100) over 70 SWATH windows per cycles with a
window size of m/z 10.
1.2.7 Data processing and extraction
DDA samples were searched against reviewed Swiss-Prot identifiers (October
2016) using Spectronaut (Biognosys, Schlieren, Switzerland).

The search was

performed using Pulsar algorithm for identification of peptides and proteins from
DDA and DIA data. BGS Factory settings were used for the search which included
specific trypsin/P digestion with a minimum of 7 amino acids, maximum of 52 amino
acids and 2 missed cleavages. Fixed modifications included carbamidomethyl (C) and
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variable modifications included acetyl (protein N-terminus) and oxidation (M). All
other options were kept as the BGS factory settings as well. Raw data files and search
results are available at Japan Proteome Standard Repository (jPOSTrepo JPST000372,
ProteomeXchange PXD008593), a publicly available data repository for proteomics
data 32.
The spectral library was then used to analyze DIA data in a DIA analysis in
Spectronaut. Samples were first converted to HTRMS files using the Spectronaut
Converter (Biognosys, Schlieren, Switzerland). All settings were run as the BGS
factory settings except “Used Biognosys’ iRT kit” was unselected and “PTM
localization” was unselected. All other settings were left the same. Raw intensity after
normalization was exported and bovine serum albumin (BSA) was monitored for
variability.
1.2.8 Data normalization
Raw normalized intensity from Spectronaut was further converted to
picomoles of protein per gram of liver tissue (pmol/g liver) use the total protein
approach (TPA) and protein yield (protein per gram of liver or PPGL) 33.

1.2.9 Statistical analysis
Non-parametric Mann Whitney U test was used to compare the differences in
demographic data and Chi-square test was used to compare the proportionality
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(GraphPad Software Inc. La Jolla, Ca). The geometric mean was calculated from nontransformed data using SPSS v26 (IBM Analytics, Armonk, NY). Gender differences
in the absolute expression of major xenobiotic and drug transporters in human liver
were carried out using a non-parametric Mann Whitney U test in Prism (GraphPad
Software Inc. La Jolla, CA). Non-parametric Spearman analysis was used for
correlation between different transporter proteins. P<0.05 was considered significant
throughout the analysis. Demographic data were reported as mean ± SEM unless
stated otherwise.
1.3 Results
SWATH-MS was used to estimate the protein expression of 13 hepatic drug
transporters (6 ABC and 7 SLC family) in membrane fractions from 20 human liver
donors. Range for all expression values fell within the range reported by Groen et al.
2018 and Wang et al. 2016 except for OATP1B3, which was reported to be ~10-fold
lower than what was measured. These data can be seen in Figure 1.5 and Table 1.4
34,35

.

1.3.1 Yield of protein per gram of liver tissue
The average protein yield (mg/g liver tissue) for all the livers was 92.56±3.97,
n=20 (Figure 1.2(a)). Protein yield was no different in females (92.23±6.46, n=9) as
compared to males (92.84±5.21, n=11). The variability in sodium/potassiumtransporting ATPase subunit alpha-1 (ATP1A1, an integral membrane marker) levels
was used to gauge the quality of the membrane fractions and % coefficient of variation
among the 20 samples was 16.62% (Figure 1.2(b)).
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1.3.2 Effect of gender on drug efflux transporters
We found that none of the investigated efflux transporters was differentially
expressed in males and females (Figure 1.3). All efflux transporters studied in this
work were found in all the liver samples. Three MRP transporters, BSEP and MDR1
(P-gp) were quantified using this assay are given in Figure 1.3. No significant gender
difference was seen in transporter proteins with efflux/uptake function as well (Figure
1.3 and 1.4).
1.3.3 Effect of gender on drug uptake transporters
Gender was found to only influence the protein abundance of OATP1B1 and
OAT7 and no other uptake transporters in this study (Figure 1.4). Males were found
to have 65.3±9.61 pmol/g liver of OATP1B1 while females were found to have
111.1±28.26 pmol/g liver (p<0.05). OAT7 was also found to be slightly significantly
lower in males (77.29±7.04 pmol/g liver) when compared to females (96.26±6.80
pmol/g liver) (p<0.05). All other uptake transporters included in the study were
detectable in all the liver samples except for OAT2 in one male sample. Genderspecific expression level and male/female ratio of transporter proteins is available at
Tables 1.2 and 1.3.
1.4 Discussion
Drug response, efficacy, and toxicity are dependent on the expression of drug
metabolizing enzymes and transporters in the intestine and liver. Differences in the
basal expression of these proteins in the human liver can contribute to significant
changes in systemic exposure of a drug. Extensive research in human has shown the
gender-related differences, which partly explain the interindividual variability in drug
22

disposition, toxicity and therapeutic response

36,37

. Gender is an essential underlying

biological factor for the development of personalized medicine. A study by the US
General Accounting Office found that 80% of FDA-approved prescription drugs
withdrawn from the market between 1997-2000 were due to higher adverse drugrelated events in women

38

. While a considerable amount of data is available on the

gender differences in transporter protein expression in rat and mice, studies are lacking
in humans

39,40

. Also, limited data are available for the gender differences in

expression of transporter proteins in humans since most available information is based
on gene expression

37

. Interestingly, a growing body of research is suggesting that

mRNA serves as a poorer surrogate than protein expression for prediction of
transporter activity 17,30,41.
The availability of human liver tissue for studying the hepatic xenobiotic
transporters remains a challenge for researchers due to ethical consideration and the
availability of tissue with adequate clinical information. Most of the samples available
from healthy people come from donors who have sadly passed away in automobile
accidents. Therefore, when possible, a judicious and parsimonious use of such tissue
is warranted to obtain maximum data. MRM-based methods of protein quantification
rely on customization of processes for each target protein before quantification.
Though such means can be adapted to quantify more than one protein at a time, the
cost and method complexity increases exponentially with an increase in the number of
target proteins

21

. Despite the benefits offered by SWATH-MS, there are some

limitations to the methodology. As the window size in SWATH increases, the noise
level increases drastically and impedes the quantification of low abundance proteins.
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Second, the runtime for sample acquisition can become time consuming.

Large

batches of samples can take weeks to run and increase the chance mass spec
variability. Nevertheless, the advantages of this technique outweigh its drawbacks.
We observed that the inter-individual variability seen in this study was much
higher than the average differences between the two genders. While a study with a
large sample set is desired to completely address the cofactors contributing to this
variability, such studies are often limited due to lack of availability of the liver tissue.
Most of the tissue that is available for commercial purchase is obtained from motor
vehicle accidents or other brain-dead donors and a detailed medical history is often
lacking. Therefore, the potential of conflicting effects from obesity or any other
undiagnosed disease cannot be ruled out. Interestingly, there are currently no reports
for any significant alteration of transporter proteins in human liver. Our findings are
also limited as we do not have a large enough sample size to separately study the
effect of obesity (BMI>30) in our sample set. Therefore, future studies with a larger
sample size are currently being planned to address the high inter-individual variability
and differential effect of obesity and diabetes.
Permeability glycoprotein 1 (P-gp)/ multidrug resistance protein (MDR1) is
predominantly responsible for efflux of cations from hepatocytes into the bile duct.
Prasad et al. found no association between age and gender with an expression of P-gp
in human livers (n=64)

30

. Cheng et al. also found no significant gender-specific

differences in human hepatic BSEP expression 40.
Multidrug resistance-associated protein (MRP2) plays an important role in the
efflux of lyophilic conjugates (glutathione, glucuronate, sulfate) 42. MRP2 is localized
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on the apical membrane of polarized hepatocytes and expressed in kidney and
intestine among other tissues

43

. MRP3 has been found to transport similar drugs to

MDR1 and 3 such as anionic drugs and conjugates44. It has been associated with the
resistance to tradition anti-cancer drugs such as methotrexate, etoposide and
teniposide. MRP3 is localized to the basolateral side of the cell45. There are currently
very little data available on MRP6. It is predominantly in the liver and kidneys on the
basolateral membrane and has been found to be upregulated similarly to MRP1 in
certain cancer cell lines 46. Recently it has been found that MRP6 is involved with the
transport of tyrosine kinase inhibitors, such as nilotinib and dasatinib, leading to
resistance in vitro 47.
Organic anion transporting polypeptides (OATPs) facilitate uptake of large
hydrophobic organic anions while smaller and hydrophilic organic anions are
transported by the organic anion transporters (OATs)

48

. OATP1B1, OATP1B3, and

OATP2B1 are the most notable transporters for drug uptake in the liver. OATP1B1
and OATP1B2 are expressed predominantly in liver whereas OAT2B1 is ubiquitously
expressed

49

. We found OATP1B1 to be significantly upregulated in females. This

matches previously published research by Yang et al. They found that OATP1B1
gene expression was increased by 1.29-fold in females

50

.

No gender-specific

expression differences of OATP1B3 or OATP2B1 were found in previous or this
current study 16,30,51.
OAT2 is highly expressed in the sinusoidal membrane of hepatocytes with
lower expression also seen in the kidney

48

. OAT7 is exclusively expressed in the

basolateral membrane of human hepatocytes in the liver and participate in the
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transport of anionic substances in exchange for butyrate

14

. We found OAT7 to be

slightly increased in females but not significant. Other groups report no statistical
difference in OAT7 between genders although there are very little reported data
available 52. Slight differences may arise as we are measuring in liver homogenate, not
a membrane fraction.

There will generally be less error due to the decreased

complexity in sample preparation, which may result in slightly different results. There
may be other factors within the demographics of the livers or the difference in
quantification methods that is the cause for the conflicting data as well. Members of
the OCT family transport organic cations down their electrochemical gradients

48

.

OCT1 and OCT3 are predominantly expressed in human liver and are localized to the
basolateral membrane of hepatocytes

53

. Prasad et al. also reported no gender

differences in expression of OATPs, OATs and OCTs in human liver 54.
We developed a SWATH-MS based method for label-free, relative quantitative
proteomics analyses of drug and xenobiotic transporters in human liver. SWATH-MS
based studies can be used for comparative global proteomics analysis and large-scale
relative protein quantification, especially for studies that a limited quantity of tissue is
available. We successfully showed that the current approach could be directly applied
to estimate the protein expression of many target proteins at once and can be further
applied to study the difference in expression in relation to demographic characteristics
or disease state. Future studies with a larger sample size are in progress to address
other factors (disease, alcohol consumption, and smoking), which may contribute to
differential expression of these transporter proteins.
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1.6 Tables
Female

Male

p-value

N (%)

9 (45%)

11 (55%)

-

Age (years)

48.11 ± 5.13

49.45 ± 5.36

p=0.86

Body weight (kg)

82.89 ± 8.7

80.82 ± 5.8

p=0.84

Height (cm)

162.56 ± 2.71

173.42 ± 2.66

p<0.01*

Body mass index (kg/m2)

31.22 ± 3.08

27.00 ± 1.92

p=0.24

Liver weight (kg)

1.33 ± 0.12

1.48 ± 0.09

p=0.32

Ethnicity (C, AA, H)

8, 1, 0

8, 3, 0

6
2
1

4
3
4

5
4

4
7

5
4

5
6

Cause of death
Anoxia
Cerebrovascular aneurysm
Head trauma
Smoking status
Non-smoker
Smoker
Alcohol consumption
No
Yes

Table 1.1 Demographics characteristics of liver donors. P value represent the
significance from Mann-Whitney U test and * represent p<0.01; C: Caucasian, AA:
Afro-American, H: Hispanic.
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Pmol protein per gram liver1
Female/Male
ratio

p-value2

20.27
(12.47-32.96)

1.26

0.476

20.8
(14.19-26.67)

17.4
(11.35-21.98)

1.2

0.324

MRP6

41.73
(37.76-46.13)

39.89
(34.59-45.92)

1.05

0.582

BSEP

-31.33)

24.62
(19.45-31.12)

0.92

0.616

MDR1

23.23
(16.52-32.66)

24.78
(17.66-34.75)

0.94

0.766

MDR3

30.20
(22.70-40.18)

30.90
(24.38-39.17)

0.98

0.892

Transporter
protein

Female

Male

MRP2

25.53
(15.14-43.15)

MRP3

Table 1.2 Gender-specific expression levels of hepatic efflux transporters.
1
Geometric mean (95% Confidence Interval), 2Student’s t-test
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Pmol protein per gram liver1
Female/Male ratio

Transporter
protein

Female

Male

OATP1B1

111.1
(71.78-171.8)

65.30
(49.66-85.70)

1.70

0.025*

OATP1B3

112.5
(95.06-133.4)

96.12
(74.82-123.6)

1.17

0.280

OATP2B1

41.84
(29.79-58.75)

39.57
(33.42-46.88)

1.06

0.726

OCT1

239.5
(151.4-379.3)

179.3
(134.3-239.3)

1.34

0.225

OCT3

25.96
(21.33-31.62)

19.91
(13.97-28.38)

1.30

0.150

OAT2

137.7
(102.3-185.4)

150.1
(104.5-215.8)

0.92

0.694

OAT7

96.26
(82.60-112.2)

77.29
(64.27-92.90)

1.25

0.06

p-value2

Table 1.3 Gender-specific expression levels of hepatic uptake transporters.
1
Geometric mean (95% Confidence Interval), 2Student’s t-test
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Transporter Protein Expression (pmol/g liver)
Transporter
protein

In-house mean
(range)

Groen mean
(range)

OATP1B1

82.95
(40.69-331.39)

17.7
(9.1-53.7)

Wang approx.
mean
(approx. range)
150
(50-300)

OATP1B3

103.2
(54.37-202.8)

16
(7.9-28.1)

60
(10-140)

OATP2B1

40.57
(20.31-90.05)

61.3
(34.5-77.8)

60
(25-125)

OCT1

204.3
(74.54-482.5)

124.3
(60.1-181.4)

175
(25-325)

MRP2

22.49
(5.93-55.53)

29.5
(19.6-39.6)

50
(15-100)

MRP3

17.35
(6.86-29.91)

6.8
(4.2-9.9)

20
(7.5-30)

MDR1

24.07
(11.09-53.04)

20.5
(12.3-25.7)

20
(8-35)

ATP1A1

232.6
(155.4-301.9)

279.3
(193.8-391.3)

N/A

BSEP

23.66
(12.13-50.98)

60.1
(25.7-92.4)

75
(25-125)

Table 1.4: Comparison of transporter expression between in-house
measurements and reported literature values. Data was taken from Groen et al.
2018 and Wang et al. 2016 and all values are expressed as pmol/g liver.
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1.7 Figures

Figure 1.1 Graphical abstract of transporter extraction, digestion and LCMS/MS analysis: Workflow for quantification of 13 clinically relevant transporter
proteins in human liver tissue using SWATH-MS
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1.2(a) Yield

1.2(b) ATP1A1

Figure 1.2: Gender difference on liver protein abundance and ATP1A1 (a
membrane protein marker). Absolute protein expression values expressed as
picomole per gram of liver tissue. The line represents the geometric mean for the
respective group and individual values are shown as aligned dots plot.
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Figure 1.3: Effect of gender on hepatic efflux transporters. Absolute protein
expression values expressed as picomole per gram of liver tissue. The line represents
the geometric mean for the respective group and individual values are shown as
aligned dots plot.
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Figure 1.4: Effect of gender on hepatic uptake transporters. Absolute protein
expression values expressed as picomole per gram of liver tissue. The line represents
the geometric mean for the respective group and individual values are shown as
aligned dots plot.
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Figure 1.5: Comparison of transporter expression between in-house
measurements and Groen et al. 2018 and Wang et al. 2016. Min to max reported
with mean shown as the middle point.
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2.1 Abstract
Background & Aims: Human liver tissue utilized in drug metabolism (DM) studies is
retrieved from brain-dead individuals receiving an array of therapeutic agents during
hospitalization. The anticonvulsant agent phenytoin, a potent cytochrome P450 (CYP)
3A4 inducer, is among such agents that potentially can impact the expression and
activity of DM enzymes. Here we identify and highlight the need to screen human
liver tissues for the presence of phenytoin.
Methods: One-hundred and six samples from an in-house repository of human livers
were screened for the presence of phenytoin and 1,702 other compounds utilizing AB
SCIEX forensic library and a TOF-instrument. Phenytoin concentrations were then
quantified in phenytoin positive tissue using LC-MS/MS. Activity levels for CYP3A4
were collected in-house as well as provided by the vendor. Expression of CYP
proteins were analyzed by an untargeted proteomic analysis. mRNA levels for all
CYPs and certain nuclear transcription factors were also measured. Non-parametric
independent sample tests were run in SPSS and comparisons with a p-value <0.05
were considered significant.
Results: Phenytoin was present in 34 of the 106 human livers (32%) and the
functional activity and protein level of CYP3A4 were significantly higher in these
samples.
Conclusions: Caution should be taken when performing studies with commercially
available liver sample and microsomes prepared thereof.

The use of ambiguous

protein expression values due to induction from phenytoin may decrease the accuracy
of PBPK models developed using such data. Whenever possible, we suggest that liver
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tissue, primary hepatocytes and liver microsomes should be screened for phenytoin to
prevent ambiguous results due to the induction of DMEs.
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2.2 Introduction
Livers from human donors contain valuable information regarding drug
metabolism and how it is affected by disease and other exogenous and endogenous
factors.

When performing drug metabolism studies using human livers, it is

imperative to know what medications are still remaining in the system as many drugs
on the market are either inducers or inhibitors of drug metabolizing enzymes1. The
FDA classifies drugs based on their potential to inhibit or induce as potent, moderate
or weak and lists examples while an exhaustive list can be found in the University of
Washington Metabolism and Transport Drug Interaction Database2,3. These drugs can
significantly impact and change the efficiency of drug metabolizing enzymes (DMEs),
specifically the hepatic cytochrome P450 (CYP) family of proteins4. By using mass
spectrometry, it is possible to screen these livers for thousands of medications and
their metabolites that may alter the metabolic profile.
Phenytoin is a highly effective anticonvulsant and one of the most commonly
prescribed antiepileptic drugs (AED) in clinical practice. Seizure is a common
complication of patients with a wide variety of brain pathologies including
spontaneous intracerebral hemorrhage, brain tumors and patients with traumatic brain
injury (TBI). Phenytoin is commonly used in TBI patients who develop seizure. It is
also recommended as either primary agent or alternative AED to Levetiracetam for
seizure prophylaxis in this population5. Post traumatic epilepsy can occur in about 57% of patients with TBI2 and prophylactic use of AEDs can prevent early post
traumatic epilepsy. In addition to phenytoin, a plethora of medications are given when
attempting to save a patient’s life and once a patient is pronounced brain dead prior to
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organ procurement. These drugs include but are not limited to sedatives, analgesics
including opioids, vasopressors, paralytics, etc6. Therefore, it can be expected that
tissue obtained from such organ donors may contain many of these drugs.
In this study, we describe the screening of commercially available human liver
samples for the presence of ~2,000 drugs and metabolites with emphasis on CYP3A
inducers. Additionally, we describe the effects seen in the protein and mRNA
expression as well as the activity levels of CYP3A4 due to the presence of phenytoin.
Finally, we demonstrate how the use of CYP3A4 values obtained from contaminated
samples can cause significant alterations in drug profiles obtained when creating a
PBPK model.

2.3 Materials and Methods
2.3.1 Chemicals and reagents
Protein preparation kit, TPCK-treated trypsin, trypsin digested β-galactosidase,
and MS tuning solution were purchased from SCIEX (Framingham, MA). Acquity
UPLC Peptide BEH C18 column and VanGuard pre-columns were obtained from
Waters Corp. (Waltham, MA).

Dithiothreitol (DTT) was purchased from Roche

Diagnostics (Indianapolis, IN). MS grade acetonitrile, methanol and formic acid were
procured from ThermoFisher (Waltham, MA). RNeasy Mini Kit was purchased from
Qiagen Inc. (Valencia, CA). Phenytoin and phenytoin-d10 were purchased from
Sigma Aldrich (St. Louis, MO). All other reagents and solvents used in this study
were of analytical grade.
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2.3.2 Human Liver Bank
Frozen human liver samples from brain dead donors were purchased from Sekisui
XenoTech LLC, Kansas City, KS. All the livers are from organ donors involved in
automobile accidents and therefore are IRB-exempt. The detailed demographics of
the donors is given in Table 2.1 including cause of death.
2.3.3 Forensic sample preparation
Human liver tissue (~50 mg) was homogenized using a bead homogenizer in 8 M
urea containing 10 mM DTT and 50 mM TEAB (tri-ethyl ammonium bicarbonate) as
described elsewhere (manuscript in preparation). For the qualitative drug screening
analysis, 400 µl of ice-cold extraction solution (acetonitrile containing 1% formic acid
and 7.5 ng THC-d3 as an internal standard) was added to 100 µl of homogenate
sample. Samples were then vortexed and sonicated.
Precipitated proteins were pelleted by spinning at 10,000 g for 5 min at 10°C.
Supernatant was collected in clean glass tubes and was dried using a SpeedVac at
room temperature (Savant SPD2010, ThermoFisher, Waltham. MA). Dried samples
were reconstituted in equal mixture of methanol and water containing 0.1% formic
acid. The samples were vortexed and sonicated for 30 sec and transferred to a
centrifuge tube. Subsequently, samples were spun at 10,000 rpm for 5 min at 10°C and
10 µL of resulting supernatant was injected into LC-MS/MS.
2.3.4 Screening for drugs
Qualitative drug screening was performed in positive ionization mode on a SCIEX
5600 TripleTOF mass spectrometer equipped with a DuoSpray ion source (AB Sciex,
Concord, Canada) coupled to an Acquity UHPLC HClass system (Waters Corp.,
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Milford, MA, USA). Drugs were separated on a Phenomenex Kinetex Phenyl-Hexyl
(4.6 x 50 mm, 2.6 µm, 100 Å). Samples were kept at 10˚C in the autosampler. The
analytical column was kept at 50˚C and injection volume was 10 µl. The
chromatographic separation was run for 25 minutes at 500 µl/min using mobile phase
A (99.9% 25 mM ammonium formate, 0.1% formic acid) and mobile phase B (99.9%
methanol, 0.1% formic acid). The solvent composition of the liner gradient is as
follows; 95% A at 0 min: 80% A at 1 min: 25% A at 14 min: 10% A from 16 – 19
min: 50% A at 22 min: and 95% A from 24 – 25 min. Analyst TF 1.7 was used to
acquire the mass spectrometry data. The SWATH-MS experiments were performed
over a m/z range of 100-700 with overlapping SWATH window widths of 20 Da
resulting in 28 windows. Declustering potential was set to 80 and a collision energy
of 35 V with a spread of 15 V was used for ions with a +1 charge state. Source
specific parameters are as follows; gas 1 (GS1): 55 psi, gas 2 (GS2): 60 psi, curtain
gas (CUR): 25 psi, source temperature (TEM): 500˚C, ionspray voltage floating
(ISVF): 5500 V.
The raw data files from SWATH-MS experiments were run through the drug
screening library for identification of drugs in the liver homogenate. The Forensic HRMS/MS Spectral Library (v2.1) was used to mine the data on MasterView v1.1
(SCIEX, Framingham, MA).
2.3.5 Quantification of phenytoin by LC-MS/MS
For quantification of phenytoin, an MRM based targeted method was used.
Phenytoin was extracted from homogenate by adding 200 µl of ice-cold extraction
solution (acetonitrile containing 1% formic acid and 7.5 ng THC-d3). Samples were
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spun down at 10,000 g for 5 min at 10°C and the supernatant was dried using a
SpeedVac at room temperature. Samples were then reconstituted in methanol. The
samples were vortexed and sonicated for 30 sec and transferred to a centrifuge tube.
Subsequently, samples were spun at 10000 g for 5 min at 10˚C and 5 µL of the
resulting supernatant was analyzed on a Xevo TQ MS (Waters Corp., Waltham, MA).
An Acquity UPLC® system coupled to a Xevo® TQ MS detector was used for
quantification of 1-pthalazinone (Waters Corp, Milford, MA, USA). Separation of
analytes was achieved over a run-time of 2.5 min on Acquity UPLC BEH C18 column
(2.1 x 50 mm, 130Ǻ, 1.7 µm) attached to Acquity UPLC BEH C18 VanGuard precolumn (2.1 x 5 mm, 130Ǻ). The flow rate was 0.5 mL/min and 5 µL of samples was
injected. The analytical column and autosampler were kept at 45°C and 10°C,
respectively. The separation of analytes was achieved over a 2.5 min linear gradient
elution method using 0.1% formic acid in water (A) and 0.1% formic acid in methanol
(B). The gradient conditions were as followed: 2% B to 98% B (0.5-1 min), 98% B (11.5 min), 98% B to 2% B at 2.25 min and maintained at 2% B for rest of the run-time.
MassLynx™ (V 4.1) and TargetLynx™ (V 4.1) were used to control the system and
integration of the analyte peaks, respectively. The ratio of analyte to internal standard
was used to quantify the phenytoin level in homogenate samples. The mass
spectrometer was operated in multiple reaction monitoring (MRM) mode and
quantification was performed in positive electrospray ionization (ESI). The source
desolvation temperature was 650°C and desolvation gas flow rate was 1000 L/h.
Mass/charge of precursor and product ions for phenytoin and phenytoin-d10 (internal
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standard) are given in Table 2.2. Measured phenytoin concentration was converted to
µg/ml based on total liver volume equations7.
2.3.6 Proteomic and mRNA studies
Preparation of microsomes, CYP3A4 functional activity, protein and mRNA levels
were obtained from the liver bank determined in our previous studies8,9. Protein
expression levels were achieved by running data dependent acquisition files through
MaxQuant (ver 1.5.2.10) where the “Total Protein Approach” was then applied in
order to convert intensity values to a picomole per mg of microsomal protein scale10.
Methods can be found in the supplementary information.
2.3.7 PBPK modeling
SimCYP population-based simulator (ver 17, Certara LP, Sheffield, UK) was
used to create a physiologically base pharmacokinetic (PBPK) model.

CYP3A4

protein and enzyme kinetic parameters for midazolam were manually changed to
reflect with and without phenytoin containing liver samples.

The Caucasian

population (Sim-NEurcaucasian) was used and 10 virtual trials with 1000 subjects per
trial were run. Male and female proportions were equal, and ages were 20-65 years
old. In vitro Vmax and Km values were obtained from Jamwal et al. and protein
expression was measured in house and previously published8,9. All other parameters
were kept as default and estimated plasma concentrations of phenytoin were used for
analysis.
2.3.8 Statistical analysis
Independent student’s t-test was used to determine the difference between groups
containing phenytoin and groups that were clean of phenytoin. Statistical values of
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p<0.05 were considered significant for the analysis. SPSS 24 (IBM Corp., Armonk,
NY) and Prism 6.0 (GraphPad Inc., La Jolla, CA) were used to perform statistical tests
and create graphs.

2.4 Results
2.4.1 Drugs found in forensic library
Drugs were considered a match if the MS/MS fragmentation pattern matched
the reference library with less than 10 ppm error. Across the 106 human liver samples,
75 different drugs were found in at least one or more samples. Phenytoin was found in
34 of the 106 samples (32%). No correlation was found between phenytoin and cause
of death. Other abundant drugs found were methylprednisolone, dexamethasone,
ofloxacin, diphenhydramine and amiodarone. A list of the other drugs found can be
seen in Table 2.3. THC-d3 was spiked into all samples as an internal control and was
found in all samples. Blanks only contained THC-d3 and a pooled human liver
microsome sample contained methylprednisolone, phenytoin and THC-d3.
2.4.2 Phenytoin concentration
Measured phenytoin levels ranged between 1 and 21 ug per g of liver tissue.
The equation Liver Volume = 0.722 * BSA1.176 was used to convert values to µg/ml7.
Values ranged between 1.7 and 16.8 µg/ml. Normal therapeutic levels of phenytoin
are between 10 and 20 ug/ml11. No correlation was found between phenytoin
concentration and mRNA, activity or protein expression. Due to the nature of the
samples, length of phenytoin therapy and time of administration is unknown.
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2.4.3 Effect of phenytoin on CYP450 expression and activity
CYP3A4 protein expression was found to be significantly higher in samples
containing phenytoin. Liver samples containing phenytoin had levels of 74.84±16.18
pmol/mg of protein while liver samples without phenytoin expressed 34.9±7.08
pmol/mg of protein (p=0.0003). Similar results were seen in CYP3A5 (p=0.032) and
CYP2B6 (p=0.004). CYP2A6 showed a similar trend but was not significant. The
expression of the remaining CYPs showed little to no significant change. These data
can be seen in Figure 2.1 and Table 2.3.
The mRNA expression of CYP2A6 (p=0.0002), 2B6 (p<0.0001), 2C8
(p=0.0001), 2C9 (p=0.0033) and 3A4 (p<0.0001) in samples containing phenytoin
were found to be significantly increased when compared those that were found to be
phenytoin free. Relative CYP3A4 mRNA expression was 2.348±1.904 and 0.45±0.71
in livers with phenytoin compared to those without phenytoin, respectively. CYP2A6,
CYP2B6 and CYP2C9 were all found to be slightly significantly increased as well
(p<0.05). These data can be seen in Figure 2.2 and Table 2.4.
CYP3A4/5 mediated testosterone hydroxylation was found to be significantly
higher in samples containing phenytoin when performed in house and by the vendor.
In house Vmax for livers containing phenytoin was found to be 268.9±92.86
pmol/min/mg protein compared to 158.8±54.57 pmol/min/mg protein for livers that
were absent of phenytoin (p<0.0001). Similar trends were seen in values measured by
the vendor at 3136±652.43 pmol/min/mg protein and 1460±191.1 pmol/min/mg
protein for livers containing phenytoin and those without, respectively. Activity levels
for midazolam hydroxylation by CYP3A4/5 (p=0.0008) and CYP2B6 (p<0.0001)
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were also found to be significantly increased when phenytoin was present. CYP2A6
was found to be slightly significantly increased (p=0.012) and CYP2C9 was found to
be significantly decreased (p=0.011). The activity of the other CYP enzymes showed
no significant difference. These data can be seen in figure Figure 2.3 and Table 2.5.
2.4.4 PBPK model
SimCyp (ver 17, Certara LP, Sheffield, UK) was used to model the elimination
of midazolam in healthy patients with parameters changed to reflect the differences of
patients on phenytoin. An IV bolus dose of 5 mg midazolam was given over 30 s. For
the no phenytoin control group, the normal population was used with 100 patients and
10 runs. For the phenytoin containing group, values for Vmax, km and CYP3A4 were
changed from 158.8 pmol/min/mg protein, 2.19 µM and 34.9 pmol/mg protein to
268.9 pmol/min/mg protein, 2.08 µM and 74.84 pmol/mg protein, respectively, to
reflect the values collected in our lab. It was found that the AUC, Cmax and Tmax
changed from 1304 ng/ml.h, 126.8 ng/ml and 0.12 h to 753.8 ng/ml.h, 120.7 ng/ml and
0.12 h respectively. AUC showed a significant decrease (p<0.0001) and changed by
about 50%. This data can be shown in Figure 2.4.

2.5 Discussion
Initially the goal of our study was purely based on curiosity of what
medications were found in the liver samples being used for proteomic and enzymatic
studies. Once the samples were run through the screening library it was discovered
that such a large percentage contained phenytoin. At that point it was decided to

53

explore the effect of phenytoin through its absolute quantification and its effect on
protein, mRNA and enzymatic activity.
In this study we found 75 unique drugs present in 106 human liver samples.
Four or more drugs were found in 50% of all samples with one sample containing as
many as 11 medications or metabolites. Phenytoin was found in one third of all
samples. Due to its abundance in samples and CYP3A4 induction characteristics,
phenytoin was chosen for further quantification13. There was no correlation between
any of the abundant drugs and cause of death. Phenytoin was expected to be seen in a
larger proportion of samples obtained from patients who passed away due to head
trauma, but it was not statistically significant14. Phenytoin is widely used either as
first line or an alternative agent to levetiracetam for seizure prophylaxis in patients
with TBI and is typically given for the first 7 days after trauma15.
In 2014, there were 288,000 hospitalizations due to TBI with 56,800 cases
leading to death in the United States16.

The average length of stay for a TBI

hospitalization is about 7 days in patients who require ICU admission and 3.2 days for
those who did not require the ICU17. As it takes between 7 and 10 days for phenytoin
to reach steady state (10-20µg/ml), it can be assumed that most patients, following the
recommended 7-day dosing for seizure prophylaxis, will have reached or be close to
steady state levels prior to declaration of brain death or organ procurment18. Full
induction effects can be expected to be the EC50 for phenytoin has been found to be
23µM or 5.8µg/ml19. Since the therapeutic range of phenytoin is 10-20µg/ml, it can
be assumed that patients receiving phenytoin were above the EC50 for the duration of
therapy20. In the situation of seizure prophylaxis for traumatic brain injury steady state
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is normally reached quicker. In some clinical practices, a loading dose of 15 to 20 mg
phenytoin equivalents (PE) per kg of IV fosphenytoin, a prodrug of phenytoin, is
given at 150 PE/min21,22. Fosphenytoin has a half-life of 15 min so it can be used to
rapidly increase the concentrations of phenytoin and therefore shorten the time it takes
to achieve steady state21, bringing the plasma concentration to around 3 µg/ml before
phenytoin therapy is started. This also avoids the untoward cardiovascular effects and
injection site pain that are associated with rapid infusion of phenytoin (greater than 50
mg/min)21. It can take up to 2 weeks to see full CYP3A4 induction as a result of
phenytoin, although effects of CYP3A4 induction can be seen as quickly as 48 hours
after the start of phenytoin therapy23,24. There was no correlation between the
concentration of phenytoin and the expression levels of CYP3A4 mRNA or protein.
This could be explained by the nonlinear pharmacokinetics of phenytoin25. Due to the
nature of the samples, it is not possible to determine if patients has been taking
phenytoin prior as opposed to during hospitalization course to achieve more of an
insight26.
Induction of CYP3A4 is a result of phenytoin binding to pregnane X receptor
(PXR) leading to co-binding with retinoid X receptor (RXR) and the eventual binding
to DNA. This results in increased production of mRNA for CYP3A4 and in turn, an
increased expression of protein. PXR binding is also responsible for the regulation of
CYP3A5, 2B6, 2C8, 2C9, 2C19 and 1A227,28. Similar effects can be attributed to the
modulation of constitutive androstane receptor (CAR) which works in the same way
as RXR but has a smaller ligand binding domain. CAR is also responsible for the
modulation of CYP1A2, 2B6, 2C9 and 3A427,29.
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An increase in a CYP3A4 leads to an increased metabolic rate or activity of the
enzyme and thus an increased clearance and decreased half-life of any given CYP3A4
substrate. For CYP3A4 to return to normal levels, it must be catabolized by the body.
It was found by Fleishaker et al., that when healthy subjects received 200 mg of
phenytoin every 8 hours, the CYP3A4 mediated metabolite of cortisol, 6βhydroxycortisol (6β-OHC), significantly increased with the first effects being noticed
at 48 hours23. The normal half-life for CYP3A4 is about 3 days, meaning that once an
inducer like phenytoin is removed from the body, the enzyme remains in an induced
state for up to 2 weeks, assuming it takes 5 half-lives to return to baseline30. Once a
donor has been declared brain dead and their family members authorize the organ
retrieval process, it can take 24-36 h before the donor is in the operating room, ready
for organ procurement31. This means that there is not time for the enzyme to return to
a non-induced state if the patient was on phenytoin.
No major inhibitors of metabolism were found in our study. An inhibitor,
unlike an inducer, binds to the protein or enzyme directly. This can be either a
reversible binding or irreversible (mechanism-based) and can either be in the active
binding site or at an allosteric location. Reversible inhibitors return to a normal level
much faster than irreversible as it will take until new enzyme is created in order to
return to normal function32. It was expected that if any inhibitors were found in the
liver samples, their effect would not affect protein or mRNA expression unless there
was irreversible binding. Additionally, activity was not expected to be affected as the
inhibitor would have been lost during ultracentrifugation during the preparation of
microsomes.
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Human liver microsomes (HLM) are commonly used and provide valuable
support to in vitro drug metabolism studies. HLMs primarily comprise of membrane
vesicles from hepatocyte endoplasmic reticulum and contain membrane bound phase I
(CYPS) and phase II enzymes (UGTs)33. It is expected that over the course of the
preparation of microsomes, drugs would be removed during any ultracentrifugation
steps. The purchased pooled liver microsome sample that we tested was shown to
contain phenytoin. The presence of an inducer indicates that donors used in the pool
should be expected to have an altered CYP protein expression. This can confound the
true functional activity of CYP enzymes. Our research suggests that commercially
obtained HLM should be screened for common CYP inducers or prepared in house
with the removal of samples containing CYP inducers.
When using liver samples containing drugs of induction, results obtained and
used in PBPK models can cause altered results. We found that using values obtained
from phenytoin containing livers, the AUC for midazolam was decreased by about
50% due to the induction of CYP3A4. This can cause a challenge when creating
disease populations where true effects may be masked or exaggerated due to the
presence of a DME altering drug such as phenytoin.
In summary, our research suggests that commercially available human liver
samples contain numerous xenobiotics from the time of death of the organ donors. It
appears that there are multiple inducers of metabolism remaining in the liver samples
and the presence of the potent CYP3A4 inducer, phenytoin, resulted in increased
protein expression, mRNA expression and activity levels of CYP3A4, as well as slight
induction in protein and mRNA expression for numerous other CYPs.
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This is a concern when developing PBPK models for translation to humans.
As we have shown, using values obtained from samples that were free of phenytoin
result in a significantly different profile when compared to samples that contained
phenytoin. This is especially important when creating models for special populations,
such as disease models, where drug metabolizing enzymes are possibly dysregulated
in the first place. The addition of phenytoin and other metabolism altering drugs to an
already perturbed metabolic profile could lead to an over or under estimation of PK
parameters when attempting to translate to the clinic.
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2.7 Tables

N
Male
Female
Height (cm)
BMI (kg/m2)
Age (years)
Ethnicity (C, AA, H)
Cause of death
Anoxia
Cerebrovascular aneurysm
Head trauma
Myocardial Infarction
Intracerebral Hemorrhage
Smoking status
Non-smoker
Smoker

Phenytoin Free

Phenytoin Containing

72
35
38
169 ± 11
34 ± 12
52 ± 13
63, 8, 2

33
21
12
170 ± 10
29 ± 8
50 ± 11
27, 2, 3

40
26
6
1
0

7
15
10
0
1

34
39

13
19

Table 2.1 Demographic data for the phenytoin containing and phenytoin free
livers. BMI: Body mass index, C: Caucasian, AA: African American, H: Hispanic
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Analyte specific mass spectrometry parameters

Analyte

Precursor
ion (m/z)

Phenytoin

253.0958

Phenytoin
D10

263.1596

Product
ion (m/z)
104.1512
182.1704
225.1000
109.1476
192.2356
235.2691

Dwell
time
(s)
0.050
0.050
0.050
0.050
0.050
0.050

Cone
voltage
(V)
20
20
20
20
20
20

Collision
voltage (V)

Retention
time (min)

35
20
10
35
20
10

1.3
1.3
1.3
1.3
1.3
1.3

Table 2.2. Analyte specific mass spectrometry parameters of phenytoin and
phenytoin D10
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Citalopram n=8
Clindamycin n=8

Fluconazole n=6
Propoxyphene n=6

Laudanosine n=4
Midazolam n=3

Metoprolol n=8
Sertraline n=8
Cyclobenzaprine n=7

Amitriptyline n=5
Lorazepam n=5
Verapamil n=5

Paroxetine n=3
Promethazine n=3
Protriptyline n=3

Diazepam n=6
Ephedrine n=6

Trimipramine n=4
Diltiazem n=4

Quetiapine n=3
Trimethoprim n=3

Table 2.3 List of drugs found in 3 or more human liver samples
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Picomole of protein per milligram of microsomal protein1
Enzyme
CYP1A2
CYP2A6
CYP2B6
CYP2C8
CYP2C9
CYP3A4
CYP3A5

No Phenytoin

Phenytoin

10.06
(7.368-13.73)
23.17
(16.46-32.6)
1.149
(0.831-1.589)
21.25
(17.1-26.4)
46.11
(40.65-52.29)
34.9
(26.88-45.32)
4.64
(3.205-6.722)

8.26
(4.604-14.82)
38.83
(23.35-64.56)
3.361
(1.832-6.166)
23.74
(15.14-37.23)
41.11
(33.24-50.84)
74.84
(48.16-116.3)
8.768
(5.418-14.19)

Phenytoin
ratio
0.82

p-value
0.541

1.68

0.074

2.93

0.0041

1.12

0.137

0.89

0.692

2.14

0.0003

1.89

0.032

Table 2.4 Effect of phenytoin on protein expression of various CYP450 proteins.
Geometric mean and 95% confidence internal of protein expression in pmol per mg of
microsomal protein for CYPs in phenytoin containing livers and non-phenytoin
containing livers. Mann Whitney U test was used to determine significance.
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Relative mRNA Expression1
Phenytoin
ratio

p-value

0.915
(0.491-1.706)

0.86

0.748

0.706
(0.414-1.206)

3.397
(1.639-7.041)

4.81

0.0002

CYP2B6

0.4011
(0.257-0.625)

3.26
(1.658-6.408)

8.13

<0.0001

CYP2C8

0.689
(0.459-1.034)

2.211
(1.35-3.62)

3.21

0.0001

CYP2C9

0.8016
(0.517-1.244)

2.432
(1.487-3.976)

3.03

0.0033

CYP3A4

0.452
(0.2933-0.696)

2.348
(1.159-4.757)

5.19

<0.0001

CYP3A5

1.008
(0.7196-1.412)

1.218
(0.847-1.754)

1.2

0.275

Enzyme

No Phenytoin

Phenytoin

CYP1A2

1.017
(0.653-1.582)

CYP2A6

Table 2.5 Effect of phenytoin on mRNA expression of various CYP450 proteins.
Geometric mean and 95% confidence internal of mRNA expression for CYPs in
phenytoin containing livers and non-phenytoin containing livers. Mann Whitney U test
was used to determine significance.
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Enzyme Activity Level1
Phenytoin
ratio

p-value

343.5
(233.5-505.4)

1.04

0.986

480.2
(356.2-647.3)

777.4
(447.5-1350)

1.62

0.012

CYP2B6
(Buproprion hydroxylation)

181.2
(136.4-240.6)

632.1
(433.2-922.4)

3.49

<0.0001

CYP2C8
(Amodiaquine N-dealkylation)

1576
(1292-1922)

1960
(1404-2738)

1.24

0.273

CYP2C9
(Dicofenace 4-hydroxylation)

2279
(2069-2509)

1682
(1368-2068)

0.74

0.011

CYP3A4
(Testosterone 6β-hydroxylation)

1430
(1141-1792)

3136
(2078-4734)

2.19

<0.0001

CYP3A5
(Midazolam 1-hydroxylation)

278.1
(221.3-349.4)

539.7
(353.1-824.8)

1.94

0.0008

Enzyme

No
Phenytoin

Phenytoin

CYP1A2
(Phenacetin O-alkylation)

327.2
(268.5-398.8)

CYP2A6
(Coumarin 7-hydroxylation)

Table 2.6 Effect of phenytoin on enzymatic activity of various CYP450 proteins.
Geometric mean and 95% confidence internal of functional activity for CYPs in
phenytoin containing livers and non-phenytoin containing livers. Mann Whitney U test
was used to determine significance.
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2.8 Figures

Figure 2.1 Effect of phenytoin on protein expression of various CYP450 proteins.
Protein expression in pmol per mg of microsomal protein of CYP1A2, 2A6, 2B6, 2C8,
2C9, 3A4 and 3A5 in livers containing phenytoin compared to livers not containing
phenytoin. Mann Whitney U test was performed and geometric mean with 95%
confidence interval are shown.
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Figure 2.2 Effect of phenytoin on mRNA expression of various CYP450 proteins.
mRNA expression of CYP1A2, 2A6, 2B6, 2C8, 2C9, 3A4 and 3A5 in livers
containing phenytoin compared to livers not containing phenytoin. Mann Whitney U
test was performed and geometric mean with 95% confidence interval are shown.
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3.1 Abstract
Background & Aims. Differential basal expression of drug metabolizing enzymes
(DMEs) and transporters in disease states can contribute to significant differences in
systemic exposure of xenobiotics. To gain insight into the alterations of these proteins
during non-alcoholic fatty liver disease (NAFLD) and diabetes, we investigated the
protein abundance and activity in 106 human liver samples.
Methods. In-solution trypsin digestion of proteins in whole tissue lysate was carried
out using pressure-cycling technology. Data were acquired in data-dependent
acquisition (DDA) and sequential windowed acquisition of all theorical ion mass
spectra (SWATH-MS) modes on a time of flight (TOF) mass spectrometer, and
absolute protein levels were determined using total protein approach. Functional
activity data from the tissue vendor were used to evaluate the effect of disease on
cytochrome P450 (CYP450) activity and further correlated with protein abundance.
Results. It was found that NAFLD altered CYP20A1, CYP2E1, CYP3A4, CYP2J2,
CYP4F2, UGT1A3, UGT1A4, UGT2A3, SULT1A1, SULT1C2, MDR1, BSEP and
MRP3 protein expression.

Diabetes was found to significantly alter the protein

expression of CYP4F2, CYP4F3, CYP4F11, SULT2A1, SULT1A1, UGT1A3,
UGT2B4, OATP1B3 and OATP2B1. It is important to point out that when livers
containing the anticonvulsant, phenytoin, were excluded from the analysis, the
differences seen in CYP3A4 were no longer significant.
Conclusions: NAFLD and diabetes alter the protein expression of some hepatic drug
disposition proteins.
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3.2 Introduction
The human liver, facilitated by several drug metabolizing enzymes (DMEs)
and transporters, is the primary organ responsible for the elimination of xenobiotics
and endogenous compounds. Nonalcoholic fatty liver disease (NAFLD), a chronic
liver condition is characterized by the presence of >5% of macrovascular steatosis in
individuals without high alcohol intake (<20 g/day for women, <30 g/day for men)
and the spectrum of the disease ranges from the benign fatty liver to severe
nonalcoholic steatohepatitis (NASH).1 NAFLD is projected to be associated with
significant economic (~$103 billion) and clinical burden in the US.2 The prevalence
of NAFLD in the USA was found to be 30% with 10.3% of patients with advanced
fibrosis.3 A recent meta-analytic report estimated higher prevalence in the Middle East
and South America with a global NAFLD prevalence of 25.24% (95% CI 22.1-28.7).4
The disease is commonly associated with hepatic fat accumulation, insulin resistance,
obesity, and cardiovascular diseases.5 Advanced stages of NAFLD are associated with
hepatocyte ballooning, lobular inflammation and/or fibrosis along with steatosis.6
Recent studies have shown a significant dysregulation of hepatic DMEs in S9
fractions from cirrhotic liver samples.7 However, the information on the expression of
other DMEs in NAFLD is limited, and wherever available, lacks consensus.8 The
current literature suggests alterations in hepatic cytochrome P450 (CYP) expression,
activity or both, however, the directionality of change lacks agreement.9-12
Diabetes and NAFLD tend to go hand in hand. In patients with type II
diabetes, the prevalence of NAFLD ranges between 40% and 70%.13 The risk factors
for diabetes are very similar to those of NAFLD as aforementioned.14 Diabetes has
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traditionally been proven to show downregulation in CYP3A4, the enzyme responsible
for metabolism of 50% of marketed drugs.15-17 It is important to study both of these
diseases in tandem as the overlap in, not only risk factors, but effect on drug
disposition can exacerbate the dysfunction of important enzymes and transporters.
The last decade has seen a rise in the use of mass spectrometry based
techniques for quantification of the protein expression.18,19 Label-free quantification
(LFQ) has emerged recently as an attractive approach for comparative analysis of
protein expression across different samples.20 Accurate and robust quantification with
LFQ approaches is complex, and different strategies for extracting quantitative data
have been developed.20 Despite being the gold standard, targeted methods of protein
quantification are costly and need significant time for optimization of mass
spectrometer conditions. A comprehensive cost comparison of different mass
spectrometry-based techniques reported significant cost savings with label-free based
quantitative proteomics.21 Recently, members of the proteomics community have
come together in order to attempt to create a standard set of rules to follow when
doing proteomic analysis in order to help reduce the variability that can be seen
between methodology and different groups.22
Traditionally, the expression and activity of DMEs have been measured in a
human liver microsomal fraction. However, the quantification of DMEs in subcellular
fractions usually suffers from batch-to-batch variability in recovery and enrichment of
proteins.23 Therefore, we developed a simple whole tissue lysate method for
simultaneous quantification of hepatic drug metabolism enzymes in human liver using
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LC-MS/MS. The method was applied to study the effect of NAFLD and diabetes on
the expression of clinically important drug metabolizing enzymes.
3.3 Materials and Methods
3.3.1 Chemicals and reagents
TPCK-treated trypsin, trypsin digested β-galactosidase and mass spectrometer
tuning solution were purchased from SCIEX, Framingham, MA. Acquity UPLC
Peptide BEH C18 analytical column and VanGuard pre-columns were procured from
Waters Corp. (Waltham, MA). 1,4-Dithiothreitol (DTT) was obtained from Roche
Diagnostics (Indianapolis, IN). Bovine serum albumin, sodium deoxycholate and
iodoacetamide (IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade
acetonitrile and formic acid were purchased from ThermoFisher (Waltham, MA).
3.3.2 Human liver and homogenate preparation
An overview of the study workflow is given in figure 1. Frozen human liver
samples from brain dead donors were purchased from Sekisui XenoTech LLC (Kansas
City, KS). The detailed demographics of the donors are given in Table 3.1. Livers
were graded by a histopathologist as previously described and were categorized as
control, NAFL or NASH

16

. Approximately 50 mg liver tissue was weighed and

homogenized in 1000 µl of homogenization buffer (8 M urea, 50 mM
Triethylammonium bicarbonate, 10 mM DTT v/v) using a bead homogenizer (Omni
Bead Ruptor, Kennesaw GA) 24. Samples were then spun at 1,000 g for 5 min and the
supernatant was collected. The total protein concentration of the resulting sample was
determined using Pierce BCA protein assay kit (ThermoFisher Scientific, Waltham,
MA). Lipid peroxidation and total cholesterol were measured as described
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previously.24 Triacylglycerides (TAG) were measured using a colorimetric assay kit
as per manufacturer’s protocol (Cayman Chemicals, Ann Arbor, MI).
3.3.3 In-solution trypsin digestion
Protein digestion was conducted as described previously with few adaptations
24,25

. Samples (~250 µg protein) were spiked with 2 µg bovine serum albumin (BSA)

and denatured with 25 µL DTT (100 mM) at 35°C for 30 min in a shaking water bath
(120 rpm). After denaturation, samples were alkylated in the dark with 25 µL IAA
(200 mM) for 30 min at room temperature. Samples were then concentrated using the
cold water, methanol and chloroform (1:2:1) precipitation method (centrifugation at
10000 rpm, 5 min at 10°C). The protein pellet was washed with ice-cold methanol and
suspended in 100 µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v
sodium deoxycholate (DOC). Further, TPCK-treated trypsin (12.5 µg) was added to
samples at a ratio of 1:20 (trypsin: protein) and samples were transferred into digestion
tubes (PCT MicroTubes, Pressure Biosciences Inc., Easton, MA). The barocycler was
run at 35°C, for 75 cycles with 60-sec pressure-cycle (50-sec high pressure, 10-sec
ambient pressure, 25 kpsi). Subsequently, 10 µg trypsin was again added to each
sample and digestion was repeated as mentioned above.
Further, to 110 µL of digested peptides sample, 10 µL of acetonitrile/water
(1:1 v/v, containing 5% formic acid) was added to precipitate DOC. Samples were
spun (10,000 rpm for 5 min at 10°C) to remove the precipitate and 100 µL supernatant
was collected. Subsequently, 25 µL of the digested peptide sample was injected on the
analytical column and were analyzed using LC-MS/MS method described below.
3.3.4 LC-MS/MS analysis
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Data-dependent analysis (DDA) was performed in positive ionization mode
using a DuoSpray™ ion source on a Sciex 5600 TripleTOF™ mass spectrometer (AB
Sciex, Concord, Canada) equipped with an Acquity UPLC HClass system (Waters
Corp., Milford, MA, USA). Gas 1 (GS1), gas 2 (GS2) and curtain gas (CUR) were
maintained at 55, 60 and 25 psi, respectively. Ion spray voltage floating (ISVF) was
kept at 5500 V while the source temperature (TEM) was 450°C. Declustering potential
(DP), collision energy (CE) and collision energy spread (CES) were set at 100, 10 and
15 respectively. During the survey scan, all the ions between a mass range of m/z 3001250 and exceeding 25 cps were used for MS/MS analysis. Former target ions were
excluded for 8 sec and the mass tolerance for TOF-MS was 50 mDa with a 100
milliseconds accumulation time. For product scan, data were acquired from 100 to
1250 m/z with an accumulation time of 75 milliseconds with a total cycle time of 3.5
sec. Product ion analysis was done under dynamic accumulation and rolling collision
energy. The SWATH-MS acquisition parameters were the same except TOF masses
were collected from m/z 300 to 1500 and SWATH data were acquired (m/z 400-1100)
over 70 SWATH windows with a size of 10 Da each.
Chromatographic separation was achieved over 180 min gradient method at
100 μL/min on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm)
preceded by an Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). Mobile
phase A was water containing 0.1% formic acid and mobile phase B was acetonitrile
containing 0.1% formic acid. Gradient conditions used were 98% A from 0 to 5 min,
98% to 70% A from 5 to 155 min, 70% to 50% A from 155 to 160 min, 50% to 5% A
from 160 to 170 min, 5% to 98% A held from 170 to 175 min. The gradient was held
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at initial conditions from 175 min until the end of the run to equilibrate the column
before the start of next run. The flow was diverted to waste for the first 8 minutes and
last 20 minutes of the acquisition. Autosampler was maintained at 10°C, and the
column was kept at 50°C. Trypsin-digested β-galactosidase peptides were injected to
monitor TOF detector mass calibration.
3.3.5 Data processing
The absolute level of proteins was determined from DDA and DIA data using
“Total Protein Approach”.26 Homogenate samples were analyzed as previously
described using Spectronaut (Biognosys, Schlieren, Switzerland). The search was
performed using Pulsar algorithm for identification of peptides and proteins from
DDA and DIA data. BGS Factory settings were used for the search which included
specific trypsin/P digestion with a minimum of 7 amino acids, maximum of 52 amino
acids and 2 missed cleavages. Fixed modifications included carbamidomethyl (C) and
variable modifications included acetyl (protein N-terminus) and oxidation (M). All
other options were kept as the BGS factory settings as well. Raw data files and search
results are available at Japan Proteome Standard Repository (jPOSTrepo JPST000372,
ProteomeXchange PXD008593), a publicly available data repository for proteomics
data 27.
The spectral library was then used to analyze DIA data in a DIA analysis in
Spectronaut. Samples were first converted to HTRMS files using the Spectronaut
Converter (Biognosys, Schlieren, Switzerland). All settings were run as the BGS
factory settings except “Used Biognosys’ iRT kit” was unselected and “PTM
localization” was unselected. All other settings were left the same. Raw intensity after
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normalization was exported and bovine serum albumin (BSA) was monitored for
variability.
Raw normalized intensity from Spectronaut was further converted to
picomoles of protein per gram of liver tissue (pmol/g liver) use the total protein
approach (TPA) and protein yield (protein per gram of liver or PPGL) 26.

3.3.6 Statistical analysis
Natural log was taken of all values for statistical tests. Student’s t-test was
used to compare the differences for two groups and a one-way ANOVA followed by
Bonferroni multiple comparison correction three or more groups. The vendor provided
functional activity was used for correlation analysis with protein concentration. The
details of the assay’s conditions are described elsewhere.24 Spearman-correlation
analysis was performed between the functional activity and protein levels. P < 0.05
was considered significant throughout the analysis. Prism 6 (GraphPad Inc., La Jolla,
CA) and SPSS 26 (IBM Corp., Armonk, NY) were used for graphing and statistical
testing, respectively.

3.4 Results
NAFLD

liver

samples

exhibited

significantly

elevated

levels

of

malondialdehyde and cholesterol (Table 3.1). The livers from NAFL and NASH
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donors were larger in weight than the control group. The total protein yield from
samples with NAFLD was marginally lower as compared to the control but was
determined to be non-significant. Donors with NAFLD also showed a trend of
increased body weight and body mass index.
3.4.1 NAFLD and CYP450 protein expression
The protein expression of CYP1A2 was significantly lower in NAFLD
samples (p<0.05). In addition, there was a significant decrease in CYP3A4 in NAFL
and NASH condition in comparison to control (p<0.05) (figure 2). Additionally,
CYP2E1 and CYP2A6 were found to be downregulated in NAFL conditions but not
NASH conditions (p<0.05).

We observed no difference in the protein levels of

CYP2D6, CYP2C8, and CYP2C9 among different study groups. A trend of lower
expression was observed for CYP2B6; however, the reduction was not significantly
different from control samples. These data can be seen in Table 3.2, Figure 3.2 and
Figure 3.3.
3.4.2 Diabetes and CYP450 protein expression
The only CYP to show any significant difference was CYP3A5, which was
downregulated in diabetes. CYP3A4 showed downregulation as well but was not
found to be statistically significant. There was no significant difference found in the
remainder of the CYPs. These data can be seen in Table 3.5, Figure 3.7 and Figure
3.8.
3.4.3 NAFLD and CYP450 enzymatic activity
Like protein abundance, CYP1A2 phenacetin O-dealkylation activity was
significantly lower in NAFL and NASH (figure 3). CYP3A4 mediated testosterone
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hydroxylation was moderately decreased in NAFLD group. CYP3A4 was tested in
samples containing CYP3A5*3/*3 as it is the nonfunctioning form of CYP3A5. The
activity of other CYP450 enzymes remained mostly similar between control and
disease state.
3.4.4 Diabetes and CYP450 enzymatic activity
None of the CYP450 enzymes showed significant alteration due to diabetes.
CYP3A4 was again tested in samples containing CYP3A5*3/*3.
3.4.5 Correlation of CYP450 enzymatic activity and protein expression
Non-parametric Spearman correlation analysis was performed between the
determined protein levels (expressed as pmol/mg protein) and vendor provided
enzyme activity (Figure 3.1). A significant correlation with varying strength was
observed for all the 9 CYP450 enzymes. CYP1A2, 2A6, 2B6, 2D6, and 3A4 exhibited
strong correlation (r>0.7) while it was moderate (r=0.5-0.7) for CYP2C8, 2C9 and
2E1. Interestingly, the association between CYP2C19 protein and activity was
weakest (r=0.395) among all the proteins.
3.4.6 NAFLD and phase II drug metabolizing enzymes
UGT1A3 was found to be significantly downregulated in NASH (p<0.05) and
downregulated in NAFL but not significant. The rest of the UGTs were found to have
no significant differences (figure 5). None of the SULT enzymes identified showed
any significant difference in either group. Data can be observed (Table 3.3, Figure
3.4 and Figure 3.5).
3.4.7 Diabetes and phase II drug metabolizing enzymes

82

SULT2A1 was found to be downregulated in diabetic livers (p<0.05) while
SULT1A1 was found to be very close to significant (p=0.60). SULT1B1, SULT1C2
and SULT1A2 remained unchanged between the three groups. UGT1A3 was found to
be downregulated in diabetes (p<0.05) and UGT2B4 had a non-significant
downregulation. The rest of the UGTs remained unchanged (Table 3.6, Figure 3.9
and Figure 3.10).
3.4.8 NAFLD and drug transporters
Bile salt export pump (BSEP) was seen to be downregulated in NASH
conditions (p<0.05).

Multidrug resistance-associated protein 3 (MRP2) showed

downregulation across the disease but did not end up being statistically significant.
MDR1 was found to be significantly upregulated in NASH (p<0.05) (Table 3.4 and
Figure 3.6).
3.4.9 Diabetes and drug transporters
None of the efflux transporters showed any significant difference across the
disease. OATP1B3 was found to have significant downregulation (p<0.01) in diabetes
while OATP1B1 showed a trend of upregulation but was not significant. OATP2B1
was also found to be significantly downregulated but not significant. OCT3 showed
significant downregulation (p<0.05) while OCT1, OAT2 and OAT7 all remained the
same across control and diabetic samples (Table 3.7 and Figure 3.11)
3.4.10 Effect of phenytoin
When livers containing phenytoin were removed from the data set, CYP3A4
was no longer found to be significantly downregulated in either the NAFL or NASH
groups. Values returned to similar levels found in the control samples. The same
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thing was seen in CYP3A4 regarding diabetes. This can be seen in Table 3.8 and
Figure 3.12.
3.5 Discussion
NAFLD and diabetes are often accompanied by other comorbidities that may
confound the observations and could partially explain the wide discrepancy in the
literature. Therefore, the results and discussion of this work are mainly restricted to the
effect of NAFLD and diabetes specifically on the expression of DMEs without any
focus on underlying conditions.
Studies in human liver microsomes have shown both downregulation of
CYP3A4 activity with the progression of NAFLD and severity of steatosis while other
studies show that there is no significant difference occurring.9,10 Similar reports of
downregulation have been previously reported in microsomes from diabetic liver
samples.15 A recent study from our group found almost a 2-fold decrease of CYP3A4
protein expression and activity in liver microsomes from NAFLD donors as well as
donors who had both NAFLD and diabetes.16 Studies in microsomal fractions from
diabetic livers found significant downregulation of CYP3A4 protein and activity but
not mRNA.15 One confounder that could explain the discrepancy that is currently
being reported is the presence of an inducer of CYP3A4, like phenytoin. As we have
previously reported, phenytoin significantly increases CYP3A4 protein, mRNA and
activity and could lead to masking the true effect of NAFLD. Our data suggest that
initially progression of NAFLD significantly lowers the protein and activity of
CYP3A4, but once the livers containing phenytoin were removed, the CYP3A4 related
levels returned to the healthy baseline (Table 3.8 and Figure 3.12).
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This study found significant downregulation of CYP1A2 in both the NAFL
and NASH livers. The same downregulation of CYP1A2 protein and activity has been
reported in human liver microsomes and hepatocytes from fatty liver grafts. 9,28 It has
also been found that CYP1A2 is decreased by about 50% in mice with obstructive
sleep apnea (OSA).29 OSA has been found to occur in 25%-30% of obese patients as
well as having an association with NAFLD.30 Patients with NAFLD and OSA could
explain a portion downregulation that is seen in CYP1A2 in this study.
CYP2E1 mediated biotransformation reactions in the liver generate a
significant amount of reactive oxygen species which further promotes the oxidative
stress in NAFLD.31 Groups have reported that CYP2E1 is induced in diabetes where
we have shown no effect either in protein expression or enzymatic activity.32,33 Groups
have also shown similar results to ours in the suppression of CYP2E1 in NAFL and
NASH.9,34,35 CYP2E1 mRNA and protein expression were found to be lower in
another study in livers from NAFLD patients whereas activity was unaltered.9
CYP2C8 protein expression was downregulated in NASH-associated liver
biopsy while CYP2C9 levels were unchanged compared to control.36 Other studies in
human tissue observed no differences in the expression of either isoform.37 No studies
have shown the effect of diabetes on CYP2C8 or CYP2C9 protein expression or
activity. CYP2C8 activity was similar in different stages of NAFLD and control livers
whereas CYP2C9 activity was reported to be higher.9 A recent study in a 3dimensional hepatocyte culture model of NAFLD, showed CYP3A4 activity was
found to be upregulated while CYP2C9 decreased.38 No studies could be found
showing any dysregulation in CYP2C8 or CYP2C9 in regards to diabetes as our data
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also show. CYP2C18 and CYP2C19 were determined to have no meaningful
difference in NAFLD or diabetes and there is no reported literature reporting any
affect either.
CYP2B6 is one of most polymorphic enzymes, which accounts for significant
variability in its expression and activity.39 Similar to CYP2B6, CYP2D6 is another
highly polymorphic enzyme responsible with varying phenotypes and degree of
metabolism of its substrates.40 Fisher et al. observed elevated CYP2B6 mRNA without
any difference in protein and activity during the progression of NAFLD.9 Current
literature reports no significant alterations in CYP2D6 expression and activity in
human liver.9 We found no significant alteration in CYP2B6 or CYP2D6 protein
expression in our NAFLD or diabetic liver samples but both cases showed a trend
toward downregulation of CYP2B6 protein expression but not enzymatic function.
CYP20A1 was found to remain the same in NAFL when compared to healthy
but downregulated in NASH (p<0.05). There is not much literature reporting the
function of CYP20A1 in regard to metabolism in the liver and it has the designation of
being an orphan CYP.41 Additional orphan CYPs, CYP4F11, CYP4F22 and CYP4V2
were found in the dataset but showed no significant difference in either stage of the
disease. CYP4F11 was also found to have no difference in NASH patients in a study
performed by Kakehasi et al.36 CYP20A1 and CYP4F11 were shown to be
significantly downregulated in diabetes and CYP4V2 showed the same trend with no
significance but like with NAFLD, there is no current literature on the effect of
diabetes.
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Three CYPs, CYP2J2, CYP4A11 and CYP4F12, were all identified to be
related to fatty acid metabolism41. We found that CYP2J2 was reduced in the NASH
group but the NAFL group remained similar to the healthy group although the
reduction was not significant. CYP2J2 has also been found to be responsible for the
metabolism of arachidonic acid into epoxyeicosatrienoic acids, which have a
cardioprotective effect.42 The downward trend of CYP2J2 and the loss of these
cardioprotective fatty acids may exacerbate the cardiovascular affects associated with
NAFLD. Both CYP4A11 and CYP4F12 showed no difference across NAFLD or
diabetes and CYP2J2 showed no difference in diabetes as well. This conflicts with
gene expression data that show overexpression of CYP4A11 in human NAFLD
livers.43,44
CYP27A1, CYP51A1, CYP8B1 and CYP7B1 are all related to sterol
metabolism41. CYP8B1 mRNA was found to be downregulated in NASH samples
while CYP7B1 mRNA has found to be increased in NASH livers.45 Our data suggest
that there is no significant difference in the protein expression of CYP8B1 but
CYP8B1 trended downwards in NASH conditions but was not statistically significant.
Both enzymes are known to be involved with the conversion of cholesterol into bile
acids. There are no literature reports on the effect of NAFLD or diabetes on CYP51A1
or CYP27A1 in humans. The downregulation of CYP27A1 and CYP7B1 could be a
factor to the increased cholesterol levels noted during the progression of NAFLD.
CYP4F2 saw trends of downregulation in NAFL and both CYP4F2 and
CYP4F3 saw similar trends in diabetes but none were significant. These enzymes are
involved with eicosanoid metabolism and along with CYP2J2, CYP4A11 and
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CYP4F11 are involved with the metabolism of arachidonic acid and other
polyunsaturated fatty acids.41,42,46,47
While the effect of NAFL on CYP450 enzymes has been extensively studied,
only limited information on the regulation of UGT enzymes is available in human.48
Hardwick and colleagues identified significant alterations in mRNA of different UGT
isoforms, but the acetaminophen glucuronidation activity was unchanged.48 UGT2B17
and UGT2B7 were identified to have similar protein levels between control and
NASH biopsy samples.36 Yalcin et al. also found that SULT1A1 protein expression
and activity were significantly decreased in steatosis and diabetes.49 Others have
reported downregulation of human SULT1A2 in NAFLD.50,51 Similarly, we found
decreased SULT1A1 protein decreased in NAFL and NASH but it was not
significant.48

SULT1A2 showed non-significant decreases in NAFL and was

significantly downregulated in diabetes (p<0.05). Multiple UGTs have been shown to
glucuronidate fatty acids like arachidonic and linoleic acid.

Specifically, in the

UGT1A family, UGT1A1, UGT1A3, UGT1A4 and UGT1A9 are seen create many of
the glucuronide metabolites.52 Our data show that there is significant downregulation
in UGT1A3 in NASH and diabetes that diabetes may exacerbate the effect of NAFLD
by decreasing the rate at which certain fatty acids can be cleared from the body. A
similar trend was seen in UGT1A4, but it was not significant. Similar to reports for
CYP450 enzymes, regulation of UGTs and SULTs is as heterogeneous; however,
there is a scarcity of data for the latter.
In addition to DMEs, xenobiotic transporters play a large role in the
elimination of a drug and are subject to dysregulation due to NAFLD and diabetes.
88

There is limited literature available assessing the effect of diabetes on human liver
transporters. The majority of papers are presenting data on BCRP, which was not
quantified in our study.53 In regard to NAFLD, our results show that there is a
significant downregulation in BSEP in the NASH group. It has been found that there
is bile acid dysregulation in NAFLD patients and samples, which could be attributed
to the downregulation of BSEP and the buildup of bile acids in the liver.54 It has also
been shown that mRNA of BSEP significantly decreases as NAFLD progresses in
both male and female populations.55

We found MDR1 or P-gp to be significantly

upregulated in NASH. This matches data published by Hardwick et al. This could be
a result of NRF2 induction due to oxidative stress conditions associated with
NAFLD.56 In regards to MRP3 where we see no significant difference, groups have
shown induction in NAFL and NASH designations while other groups show increased
protein in only NASH samples.55-57 OATP1B3 was significantly upregulated in
diabetes but not NAFLD and the other OATP family proteins both saw non-significant
differences in diabetes and NAFLD. The 8 other clinically relevant transporters that
were measured in our samples showed little to no difference across the NAFLD and
diabetes grouping. It has been reported that the majority of basolateral efflux
transporters are upregulated in NASH while uptake transporters are downregulated.56
Recently, numerous transporters were shown to be changing mainly from steatosis to
NASH livers. There was a significant decrease found in OATP1B1, OATP1B3,
OATP2B1, OAT2 and NTCP while OAT7, MDR1 and MRP3 showed significant
increase.57 As NAFLD is a multifaceted disease with numerous variables, it is
important to look at each of the individual variables to determine their impact. This is
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difficult, though, as it is generally not possible to procure samples that are specific
enough in their pathology to perform a valid analysis. Another component that can
cause variability in reported values is the method of expressing the transporter units.
Some groups report as pmol/mg of membrane protein while other factor protein
extraction into the equation and use pmol/g of liver. As the extraction of protein can
differ from liver to liver based on the amount of fat or fibrotic tissue present, this can
add additional differences to final protein expression values.
One potential explanation for such a wide discrepancy in literature can be
attributed to the interindividual variability, and sample size used to derive the
inferences. The availability of human liver tissue for studying the hepatic drug
metabolizing enzymes remains a challenge for researchers due to ethical consideration
and the availability of tissue with adequate clinical information. Additionally, the
methods of reporting expression, especially with protein, can differ from group to
group. The differences that can occur expressing in terms of mg of membrane protein,
mg of total protein or g of liver can cause high variability. Misuse of classification
systems and incorrect characterization of study samples may have also lead to
different conclusions.58 The sampling of human liver tissue is critical in the
identification of the perturbations in the expression of proteins. Histopathological
differences were found in liver biopsies from the right and left lobes of bariatric
patients.59 Our knowledge of the drugs that the donors were taking at the time of death
is limited only to the information passed on by the vendor. These possible medications
have been shown by our group to significantly alter the metabolic profile of CYP3A4
and could, therefore, be suppressing the true effect of a disease state. Furthermore,
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there were no data available on the duration of hospitalization of donors before the
organs were harvested.
To summarize, our research shows that CYP1A2 and BSEP are highly affected
by NAFLD. CYP3A4 initially appears to be affected but once phenytoin is accounted
for, these differences become non-significant. The remainder of significantly altered
CYPs seem to be mainly related to fatty acid synthesis and sterol metabolism. Apart
from CYP1A2 and CYP3A4, the majority of CYPs related to drug metabolism seem
to be unaffected by NAFLD. A lack of adverse clinical reports also indicates that most
drugs appear to be well-tolerated by these patients despite the differences in the
expression of drug metabolism enzymes. Additionally, glucuronidation by UGTs
seems to be affected by both NAFLD and diabetes leading to a possible exacerbated
effect, especially related to the formation of bile acids. It appears that majority of
enzymes that are affected by NAFLD are related to the fatty acid metabolic or bile
acid synthesis pathways rather than the drug metabolic pathway. Multiple factors in
NAFLD and diabetes may affect the expression and activity of DMEs, and a
comprehensive study needs to be conducted to answer some of the questions around
the discrepancies observed in the literature.
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3.7 Tables
N
Age (y)
Female
Male
Caucasian
Afro-American
Hispanic
Body weight (kg)
BMI (kg/m2)
Liver weight (g)
Malondialdehyde
(nmol/mg protein)
Cholesterol
(µg/g liver)
Triacyl glycerides
(mg/g liver)
PPGL (mg/g)
Non-diabetic
Diabetic

Control
42
46.5 (41.9 - 51.6)
16
26
33
8
1
83.5 (76.2 - 91.5)
29.3 (26.5 - 32.3)
1482.4
(1374.9 - 1598.3)

NAFL
34
52.8 (49.5 - 56.4)
19
15
20
1
3
89.8 (80.6 - 100.1)
31.2 (28 - 34.8)
1798.5
(1603.2 - 2017.6) *

NASH
30
50.8 (47.3 - 54.5)
15
15
28
1
1
92.7 (86 - 99.9)
32.2 (29.9 - 34.7)
1839
(1678.4 - 2014.9) **

0.6 (0.5 - 0.7)

0.9 (0.8 - 1.2) **

1.2 (1 - 1.6) **

14.2 (12.4 - 16.2)

18.7 (16 - 21.9) **

20.8 (17.9 - 24.1) **

15.8 (12.01 - 20.79)

14.44 (12.1 - 17.23)

78.9 (71.8 - 86.8)
19
15

79.8 (72.1 - 88.3)
13
17

12.18 (10.01 14.82)
83.1 (77.4 - 89.3)
21
21

Table 3.1 Demographic characteristics of control, NAFL and NASH groups.
BMI: Body-mass index; PPGL: Protein per gram liver. Adjusted p-value from
Bonferroni comparison correction. * and ** represent p-value <0.05 and <0.01,
respectively.
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Picomole of protein per gram of liver
Enzyme
CYP1A2
CYP20A1
CYP27A1
CYP2A6
CYP2B6
CYP2C8
CYP2C9
CYP2C18
CYP2C19
CYP2D6
CYP2E1
CYP2J2
CYP3A4
CYP3A5
CYP3A7
CYP4A11
CYP4A22
CYP4F2
CYP4F3
CYP4F11
CYP4F12
CYP4V2

Healthy

NAFL

NASH

303.0
(179.5-421.3)
49.46
(40.66-60.17)
264.9
(189.0-371.2)
618.8
(413.2-926.6)
102.9
(65.61-161.5)
350.2
(227.8-538.3)
908.2
(641.2-1287)
25.19
(19.50-32.53)
32.93
(23.89-45.38)
148.9
(106.0-209.1)
853.5
(661.7-1102)
43.60
(34.66-54.83)
447.6
(300.4-667.0)
56
56.63
(35.54-90.23)
18.34
(10.53-31.95)
403.0
(300.2-540.9)
58.75
(40.66-84.89)
194.2
(138.0-273.4)
231.6
(174.4-307.5)
125.3
(98.80-159.0)
19.35
(16.38-22.85)
42.52
(34.55-52.33)

116.0
(66.41-202.5)
41.36
(33.25-51.44)
300.0
(200.3-449.3)
315.5
(183.4-542.9)
46.57
(26.62-81.48)
205.8
(128.3-330.0)
567.5
(365.6-880.8)
23.62
(16.77-33.26)
29.39
(17.98-48.06)
105.5
(63.13-176.2)
420.2
(287.7-613.7)
40.14
(29.48-54.66)
230.3
(139.3-380.7)
32.55
(22.79-46.48)
14.92
(8.564-26.00)
367.0
(267.6-503.4)
64.75
(49.38-84.90)
118.7
(76.00-185.5)
223.1
(161.7-307.9)
106.9
(79.94-143.1)
17.40
(13.24-22.87)
41.87
(30.83-56.88)

128.4
(73.99-222.8)
33.67
(25.46-44.52)
262.4
(164.2-419.5)
432.1
(294.9-633.1)
62.91
(39.87-99.28)
309.6
(198.7-482.6)
629.4
(366.4-1081)
27.74
(19.67-39.14)
42.36
(27.45-65.39)
109.1
(68.39-174.0)
557.4
(337.4-920.9)
30.38
(22.20-41.59)
254.7
(169.8-381.9)
39.60
(25.42-61.71)
7.846
(4.338-14.19)
287.8
(169.5-488.8)
61.47
(42.09-89.76)
207.7
(143.9-299.7)
260.8
(178.6-380.8)
108.1
(80.63-145.0)
16.61
(12.45-22.16)
36.76
(24.20-55.84)
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Healthy vs
NAFL1

Health vs
NASH1

0.013

0.040

0.607

0.039

1

0.880

0.041

0.488

0.051

0.429

0.129

1

0.285

0.604

1

1

1

1

0.674

0.863

0.012

0.253

1

0.165

0.019

0.040

0.200

0.758

1

0.103

1

0.460

1

1

0.083

0.131

1

1

1

1

1

0.966

1

1

CYP51A1
CYP7B1
CYP8B1

48.28
(33.96-68.65)
17.96
(13.42-24.03)
254.3
(162.9-397.0)

47.30
(34.44-64.95)
18.26
(13.98-23.85)
368.8
(307.2-442.8)

47.22
(31.01-71.92)
11.40
(7.499-17.33)
322.3
(234.8-443.2)

1

1

1

0.131

0.360

1

Table 3.2 Effect of NAFLD on protein expression of various CYP450 proteins.
Geometric mean and 95% confidence internal of protein expression in pmol per g of
liver tissue. 1 P-value Bonferroni multiple comparison correction after ANOVA

99

Picomole of protein per gram of liver
Enzyme
SULT1A1
SULT1A2
SULT1A3
SULT1B1
SULT1C2
SULT2A1
UGT1A1
UGT1A3
UGT1A4
UGT1A6
UGT1A9
UGT2A3
UGT2B4
UGT2B7
UGT2B10
UGT2B15
UGT2B17
UGT3A1

Healthy

NAFL

NASH

883.8
(624.3-1251)
70.74
(46.28-108.1)
21.92
(16.69-28.78)
134.9
(98.96-184.0)
85.01
(51.50-140.3)
1548
(1046-2291)
147.8
(104.4-209.2)
161.3
(127.0-204.8)
294.6
(212.8-407.8)
170.2
(121.5-238.3)
592.2
(422.5-830.1)
50.91
(40.70-63.66)
559.0
(435.1-718.2)
5
1359
(906.8-2037)
648.5
(493.1-852.8)
203.4
(142.7-290.1)
896.5
(607.6-1323)
17.81
(12.65-25.07)

579.1
(380.2-882.2)
63.55
(39.66-101.9)
21.03
(13.82-31.99)
131.0
(95.42-179.9)
164.2
(86.99-310.0)
1099
(703.7-1715)
139.8
(93.14-209.9)
109.2
(76.83-155.2)
169.6
(106.2-270.9)
158.6
(104.8-239.9)
531.2
(336.4-838.9)
59.72
(44.03-81.00)
463.1
(353.2-607.4)
1137
(732.0-1765)
382.7
(243.3-602.0)
251.9
(170.1-373.0)
951.9
(598.2-1514)
12.01
(7.297-19.77)

539.3
(298.9-973.2)
89.15
(58.59-135.6)
23.93
(18.05-31.71)
142.1
(102.4-197.4)
116.5
(62.93-215.6)
1717
(1146-2573)
629.4
(366.4-1081)
117.7
(72.53-190.9)
172.9
(108.6-275.4)
240.2
(165.9-347.8)
477.1
(268.1-848.7)
62.59
(43.31-90.46)
395.2
(270.6-577.2)
1185
(705.3-1992)
414.0
(255.1-671.6)
276.8
(175.5-436.5)
1104
(715.9-1703)
16.80
(8.865-31.83)

Healthy vs
NAFL1

Healthy
vs NASH1

0.394

0.277

1

1

1

1

1

1

0.227

1

0.348

1

1

1

0.194

0.013

0.151

0.203

1

0.781

1

1

1

0.809

1

0.314

1

1

0.144

0.306

1

0.744

1

1

0.811

1

Table 3.3 Effect of NAFLD on protein expression of various phase II metabolic
proteins. Geometric mean and 95% confidence internal of protein expression in pmol
per g of liver tissue. 1 P-value Bonferroni multiple comparison correction after
ANOVA
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Picomole of protein per gram of liver
Enzyme
MDR1
MDR3
BSEP
MRP2
MRP3
MRP6
OCT1
OCT3
OAT2
OAT7
OATP1B1
OATP1B3
OATP2B1

Healthy

NAFL

NASH

25.89
(21.31-31.45)
26.68
(21.41-33.25)
22.87
(19.80-26.42)
14.13
(11.16-17.90)
11.79
(9.726-14.29)
29.04
(23.21-36.34)
79.57
(53.77-117.8)
18.66
(14.79-23.54)
91.46
(67.19-124.5)
53.62
(40.52-70.97)
68.27
(56.50-82.49)
67.65
(53.50-85.54)
28.16
(21.79-36.39)
56

24.51
(17.77-33.80)
19.52
(16.22-23.50)
27.83
(22.08-35.07)
13.09
(10.07-17.01)
10.09
(7.703-13.21)
27.42
(20.78-36.17)
102.9
(73.75-143.6)
21.97
(17.62-27.38)
73.03
(49.36-108.1)
55.09
(39.56-76.72)
65.58
(50.28-85.54)
49.27
(33.64-72.17)
26.87
(19.43-37.16)

39.41
(32.34-48.03)
24.96
(17.18-36.28)
18.20
(15.42-21.47)
14.33
(10.70-19.18)
8.260
(5.822-11.72)
30.27
(23.00-39.85)
101.8
(64.15-161.5)
22.40
(17.01-29.50)
76.32
(51.08-114.0)
61.27
(40.34-93.06)
54.19
(38.13-77.01)
56.15
(37.82-83.35)
30.97
(23.38-41.01)

Healthy
vs NAFL1

Healthy
vs NASH1

1

0.043

1

1

0.345

0.020

1

1

1

0.191

1

1

0.980

1

0.975

0.863

1

1

1

1

1

0.608

0.451

1

1

1

Table 3.4 Effect of NAFLD on protein expression of various transporter proteins.
Geometric mean and 95% confidence internal of protein expression in pmol per g of
liver tissue. 1 P-value Bonferroni multiple comparison correction after ANOVA
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Picomole of protein per gram of liver
Enzyme
CYP1A2
CYP20A1
CYP27A1
CYP2A6
CYP2B6
CYP2C8
CYP2C9
CYP2C18
CYP2C19
CYP2D6
CYP2E1
CYP2J2
CYP3A4
CYP3A5
CYP3A7
CYP4A11
CYP4A22
CYP4F2
CYP4F3
CYP4F11
CYP4F12
CYP4V2

Non-Diabetic

Diabetic

198.9
(133.6-296.1)
45.52
(38.67-53.59)
292.1
(216.3-394.6)
483.8
(339.4-689.7)
85.44
(60.41-120.9)
348.8
(252.4-482.1)
737.0
(530.4-1024)
28.01
(23.3-33.57)
37.96
(28.46-50.63)
143.9
(105.5-196.2)
606.7
(445.9-825.7)
35.36
(27.78-45.01)
406.8
(296.4-558.1)
59.14
(40.73-85.88)
13.28
(8.262-21.36)
361.7
(272.1-480.8)
58.24
(44.36-76.48)
196.2
(144.3-266.6)
262.8
(209.2-330.1)
117.3
(91.74-150.0)
18.14
(15.09-21.81)
43.38
(35.73-52.67)

139.5
(92.22-211.0)
36.73
(29.84-45.20)
258.5
(191.9-348.1)
388.6
(268.6-562.1)
55.89
(36.62-85.27)
241.1
(165.9-350.3)
652.1
(461.1-922.2)
22.69
(17.18-29.97)
32.49
(23.51-44.91)
110.5
(78.25-156.1)
533.8
(397.9-716.2)
39.05
(31.31-48.69)
253.4
(178.8-359.2)
34.26
(24.71-47.51)
14.30
(9.225-22.16)
341.1
(257.9-451.1)
65.22
(50.35-84.49)
150.1
(110.8-203.4)
200.8
(152.2-264.9)
99.43
(81.06-122.0)
18.25
(15.13-22.03)
39.78
(20.50-51.88)
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Student’s t test
p-value1
0.219
0.124
0.599
0.506
0.126
0.197
0.649
0.226
0.614
0.272
0.583
0.501
0.078
0.029
0.825
0.871
0.482
0.313
0.135
0.326
0.909
0.663

CYP51A1
CYP7B1
CYP8B1

44.49
(33.81-58-52)
16.80
(13.06-21.61)
277.0
(204.5-375.1)

52.05
(39.48-68.83)
15.25
(11.90-19.55)
293.8
(218.8-394.5)

0.422
0.607
0.807

Table 3.5 Effect of diabetes on protein expression of various CYP450 proteins.
Geometric mean and 95% confidence internal of protein expression in pmol per g of
liver tissue. 1 P-value from student’s t-test.
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Enzyme
SULT1A1
SULT1A2
SULT1A3
SULT1B1
SULT1C2
SULT2A1
UGT1A1
UGT1A3
UGT1A4
UGT1A6
UGT1A9
UGT2A3
UGT2B4
UGT2B7
UGT2B10
UGT2B15
UGT2B17
UGT3A1

Non-Diabetic

Diabetic

879.0
(628.9-1228)
88.78
(63.25-124.6)
21.70
(16.68-28.24)
117.5
(86.44-159.8)
99.84
(67.53-147.6)
1986
(1540-2561)
148.7
(110.3-200.3)
149.5
(121.7-183.6)
247.8
(183.6-334.5)
178.2
(134.0-237.1)
567.5
(419.9-767.1)
57.90
(47.24-70.96)
542.4
(424.2-693.6)
1414
(1006-1989)
494.2
(356.6-684.9)
263.8
(202.5-343.7)
1212
(894.3-1644)
13.22
(9.019-19.36)

544.8
(384.2-772.6)
65.63
(47.07-91.51)
21.82
(17.13-27.80)
134.6
(107.8-168.0)
115.4
(69.51-191.7)
1091
(762.8-1562)
127.0
(93.85-191.7)
99.13
(76.83-155.2)
196.8
(140.8-275.5)
189.8
(142.7-252.4)
503.3
(349.0-725.9)
54.30
(42.54-69.31)
403.7
(327.5-497.6)
1088
(784.4-1508)
438.5
(322.5-596.2)
227.0
(161.4-319.3)
857.0
(605.0-1214)
15.18
(10.80-21.34)

Student’s t-test
p-value1
0.060
0.207
0.975
0.483
0.643
0.012
0.463
0.019
0.300
0.600
0.585
0.621
0.065
0.261
0.598
0.456
0.130
0.652

Table 3.6 Effect of diabetes on protein expression of various phase II metabolic
proteins. Geometric mean and 95% confidence internal of protein expression in pmol
per g of liver tissue. 1 P-value from student’s t-test.
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Enzyme
MDR1
MDR3
BSEP
MRP2
MRP3
MRP6
OCT1
OCT3
OAT2
OAT7
OATP1B1
OATP1B3
OATP2B1

Non-Diabetic

Diabetic

27.78
(23.69-32.58)
24.56
(20.06-30.06)
21.48
(18.56-24.87)
14.13
(11.86-17.99)
9.583
(7.761-11.83)
29.75
(24.19-36.60)
96.76
(71.16-131.6)
23.75
(20.76-27.16)
80.62
(60.32-107.8)
47.62
(36.42-62.27)
55.40
(44.02-69.72)
70.50
(57.46-86.49)
31.61
(25.56-39.11)

28.10
(22.47-35.14)
27.69
(22.49-34.09)
18.71
(16.34-21.41)
12.55
(10.31-15.27)
10.45
(8.618-12.68)
28.31
(23.86-33.59)
84.12
(61.19-115.6)
17.90
(14.39-22.26)
78.90
(60.79-102.4)
64.08
(50.79-80.85)
70.07
(59.13-83.04)
44.08
(33.02-58.85)
24.65
(19.56-31.07)

Student’s t test
p-value1
0.935
0.146
0.830
0.285
0.591
0.763
0.513
0.028
0.853
0.106
0.098
0.010
0.125

Table 3.7 Effect of diabetes on protein expression of various transporter proteins.
Geometric mean and 95% confidence internal of protein expression in pmol per g of
liver tissue. 1 P-value from student’s t-test.
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Effect of phenytoin on CYP3A4 in NAFLD and diabetes
Enzyme

Healthy

NAFL

NASH

Phenytoin Free

N=29

N=26

N=17

All Livers

N=42

N=34

N=30

Protein
(Phenytoin Free)
Protein
(All Livers)
Activity
(Phenytoin Free)
Activity
(All Livers)

399.2
(244.9-650.8)
447.6
(300.4-667.0)
1867
56
(1384-2519)
2544
(3379-1915)

277.7
(152.8-504.7)
230.3
(139.3-380.7)
1071
(688.1-1668)
1412
(919.6-2168)

250.4
(159.5-393.1)
254.7
(169.8-381.9)
1214
(902.2-2272)
1377
(1035-2186)

Non-Diabetic

Diabetic

Phenytoin Free

N=35

N=31

All Livers

N=53

N=43

Protein
(Phenytoin Free Livers)
Protein
(All Livers)
Activity
(Phenytoin Free Livers)
Activity
(All Livers)

398.9
(268.8-591.9)
406.8
(296.4-558.1)
1496
(1029-2173)
1972
(1448-2688)

230.1
(147.7-358.4)
253.4
(178.8-359.2)
1256
(1002-1828)
1549
(1240-2155)

ANOVA pvalue

0.304
0.009
0.099
0.042

Student’s t-test
p-value

0.276
0.063
0.300
0.096

Table 3.8 Effect of phenytoin on protein expression and enzymatic activity of
CYP3A4. Geometric mean and 95% confidence internal of protein expression in pmol
per g of liver tissue. P-value from ANOVA for NAFLD samples. P-value from Pvalue from student’s t-test for diabetic samples.
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Figure 3.1 Correlation of protein expression and functional activity of CYP
enzymes. r represents non-parametric Spearman correlation coefficient.
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Figure 3.2 Effect of NAFLD on protein expression of various CYP450 proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from one-way ANOVA run on ln transformed data with Bonferroni correction. *
and ** represent p-value <0.05 and <0.01, respectively.
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Figure 3.3 Effect of NAFLD on protein expression of various CYP450 proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from one-way ANOVA run on ln transformed data with Bonferroni correction. *
and ** represent p-value <0.05 and <0.01, respectively.
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Figure 3.4 Effect of NAFLD on protein expression of various SULT proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from one-way ANOVA run on ln transformed data with Bonferroni correction. *
and ** represent p-value <0.05 and <0.01, respectively.
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Figure 3.5 Effect of NAFLD on protein expression of various UGT proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from one-way ANOVA run on ln transformed data with Bonferroni correction. *
and ** represent p-value <0.05 and <0.01, respectively.
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Figure 3.6 Effect of NAFLD on protein expression of various drug transporter
proteins. Graphs represent Tukey box plots with median (horizontal line); + represent
mean; P-value from one-way ANOVA run on ln transformed data with Bonferroni
correction. * and ** represent p-value <0.05 and <0.01, respectively.
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Figure 3.7 Effect of diabetes on protein expression of various CYP proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from independent Student’s t-test run on ln transformed data. * and ** represent
p-value <0.05 and <0.01, respectively.
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Figure 3.8 Effect of diabetes on protein expression of various CYP450 proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from independent Student’s t-test run on ln transformed data. * and ** represent
p-value <0.05 and <0.01, respectively.
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Figure 3.9 Effect of diabetes on protein expression of various UGT proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from independent Student’s t-test run on ln transformed data. * and ** represent
p-value <0.05 and <0.01, respectively.
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Figure 3.10 Effect of diabetes on protein expression of various SULT proteins.
Graphs represent Tukey box plots with median (horizontal line); + represent mean; Pvalue from independent Student’s t-test run on ln transformed data. * and ** represent
p-value <0.05 and <0.01, respectively.
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Figure 3.11 Effect of diabetes on protein expression of various drug transporter
proteins. Graphs represent Tukey box plots with median (horizontal line); + represent
mean; P-value from independent Student’s t-test run on ln transformed data. * and **
represent p-value <0.05 and <0.01, respectively.
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Figure 3.12 Effect of phenytoin on CYP3A4 protein expression and enzymatic
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correction (NAFLD). * and ** represent p-value <0.05 and <0.01, respectively.
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4.1 Abstract
Background & Aims. Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent
disease in our modern society. It is crucial to develop an accurate mouse model that is
representative of the disease. The American Lifestyle Induced Obesity Syndrome
(ALIOS) model aims to cause mice to develop NAFLD through diet and lifestyle
management simulating western culture. Determining the proteomic changes
occurring to the drug metabolizing profile is critical to assess if the model accurately
translates to humans.
Methods. Pressure-cycling technology aided trypsin digestion was carried out on the
whole tissue lysate from human and mouse livers. Both a data-dependent and dataindependent acquisition method was used to acquire data on a time of flight (TOF)
mass spectrometer. Absolute protein quantification was determined and fold change
analysis in each species was performed between the healthy and disease state.
Results. It was found that about 75% of cytochrome P450s (CYPs) enzymes related to
xenobiotic metabolism showed changes that were comparable between mouse and
humans. Phase II metabolic enzymes were accurate 50% of the time and transporter
differences were accurate in the two proteins that were measured in mouse liver. The
enzymes that did not properly match up were mainly proteins that had poor orthology
between the species.
Conclusions: The ALIOS model looks to be a reasonable representation of the
majority of drug metabolism related CYPs.
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4.2 Introduction
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease in modern
society. It has been found that 30% of the population in the US has some degree of
NAFLD, with 10.3% of patients exhibiting advanced fibrosis resulting in an
approximate $103 billion economic burden within US1,2. NAFLD is characterized by
the presence of >5% macrovascular steatosis within the liver in people with low to no
alcohol intake (<20g/day for females, <30g/day for males)3.

Both healthy and

diseased livers have ranging levels of hepatocyte ballooning and lobular inflammation
however NAFLD does not truly develop until steatosis occurs. NAFLD can range
from benign fatty liver to nonalcoholic steatohepatitis (NASH) and can eventually lead
to hepatocellular carcinoma. While the benign stages of the disease are reversible,
once a liver becomes fibrotic, the damage cannot be repaired with current therapeutic
intervenations4.

Other

disease

states

including

obesity,

insulin

resistance,

cardiovascular diseases, and lipotoxicity are all generally associated with NAFLD as
well5.
As the physiological characteristics of the liver change as the disease progresses, it
is important to determine how the disease affects the function of drug metabolizing
enzymes and transporters concentrated within the liver.

Drug transporters are

responsible for the passage of drugs and drug metabolites from the blood into the cell
and vice versa6. They, along with drug metabolizing enzymes are responsible for the
elimination of drugs from the body under normal circumstances.
Mouse models are an important starting point for the study of diseases including
NAFLD. When looking at models, mice have multiple advantages when compared to
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in vitro cell models. Mouse models are better able to translate to humans as the
complexity of a whole animal can more accurately portray human disease state than a
cell culture model. Diet, genetics, and lifestyle are all able to be modified in order to
create the most accurate model. It is unrealistic, though, to assume that one animal
model will represent all aspects of a disease. Therefore, it is important to realize that
numerous models may be needed to understand different disease aspects. Additionally,
species differences can lead to decreased accuracy of these models due to differences
and variations in numerous genes that are expressed in humans and mice.7 Though
there are some genetic differences, the genomes of mice and human are strikingly
homologous leading to the assumption that mice are a good representative model.
Some other factors that need to be taken into consideration when comparing a
mouse model to a human is their difference in size, metabolic rate and lifespan.8
Regarding specific NAFLD models, not only the genome and proteome have to
accurately reflect the changes that are occurring in humans but the histological
changes that are seen must be consistent too. Steatosis, lobular inflammation,
hepatocyte ballooning and fibrosis must all develop as they are all involved in the
classification and designation of scoring a liver to determine the severity of NAFLD.9
There have been numerous cases of drugs that show great potential in the treatment of
NAFLD in preclinical mouse studies but completely fail once in the clinic.10
New tools are being developed to assist with the validation and exploration of the
mouse proteome in relation to human. Mass spectrometry-based protein quantification
methods have begun to rise as a gold standard over the past decade. While targeted
quantification methods remain the current gold standard, label-free quantification
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(LFQ) methods are becoming ever more popular due to the cost effectiveness and
reduction of time required to prepare and analyze samples. Although less reproducible
as targeted methods, LFQ methods are proving their worth when employed correctly.
Tools like this are allowing a deep dive into the proteomes of different mouse models
to help determine if the proteome is seeing the same changes in NAFLD that are being
noted in humans. This can provide validation when translating to humans and the
clinic and will help with the development of new drugs to treat NAFLD faster and for
less money.

4.3 Materials and methods
4.3.1 Chemicals and reagents
Acquity UPLC Peptide BEH C18 analytical column and VanGuard precolumns we purchased from Waters Corp. (Waltham, MA). MS tuning solution,
TPCK-treated trypsin and trypsin digested β-galactosidase were procured from SCIEX
(Framingham, MA). Bovine serum albumin (BSA), sodium deoxycholate (DOC) and
iodoacetamide (IAA) were purchased from Sigma Aldrich (St. Louis, MO). 1,4Dithiothreitol (DTT) was obtained from Roche Diagnostics (Indianapolis, IN). MS
grade acetonitrile and formic acid were purchased from ThermoFisher (Waltham,
MA).
4.3.2 Human liver bank
Frozen human liver samples were purchased from Sekisui XenoTech LLC
(Kansas City, KS).

All liver samples were procured from patients involved in

automobile accidents, therefore are IRB-exempt. All livers came from brain dead
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donors ranging from 21 to 64 years old. A list of the detailed demographic data is
shown in Table 1. Human livers were graded by a histopathologist as previously
described and further classified as a control, NAFL or NASH liver11. Mouse livers
were similarly graded and scored by a board certified veterinary pathologist using the
method described by Kleiner et al12.
4.3.3 Animal Treatment and Study Design
C57BL/6 (n=16) aged 4 weeks were purchased from Jackson Laboratories (Bar
Harbor, ME USA) and housed with at least 2 mice per cage under 12-hour light/day
cycles. Mice were acclimated for 1 week prior to having bedding pooled and
redistributed weekly for two weeks. Mice were fed either a low-fat diet (LFD)(12%
kcal from fat)(n=8) or a high-fat diet (HFD)(45% kcal from fat)(n=8). Bedding was
pooled weekly within treatment groups, mixed and redistributed within the treatment
group to account for a microbial cohousing effect13-15. Water consumption, food intake
and body weight were monitored weekly. At the end of 18 weeks, 16 mice were
sacrificed and whole blood was collected using cardiac puncture. Whole blood was
centrifuged and immediately separated into two aliquots for future analysis. Mice
were sacrificed by isoflurane and decapitation following blood collection.
4.3.4 Mouse Diet Selection
The ALIOS (American Lifestyle Induced Obesity Syndrome) diet models a
western diet while also pairing with sedentary behavior and sugar rich drinking water.
The diet consisted of hydrogenated vegetable oil (trans and saturated fats) and
cholesterol (0.2% w/w) in addition to water containing high sugar content (42 g/L:
55% w/v fructose, 45% w/v glucose)(TD.120330). Diets were prepared by Envigo-
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Teklad (Madison, WI USA) and chosen based on previously cited studies that show
the development of NASH phenotypes including liver neutral lipid accumulation,
inflammation and necrosis within 16 weeks. The dietary inclusion of cholesterol and
high fructose/glucose in drinking water also has been shown to further promote the
NASH phenotype16-18. A custom, grain free, phytoestrogen free diet (TD.2020) was
used as the low-fat diet control.
4.3.5 Tissue preparation
One ml of homogenization buffer (8 M urea, 50 mM triethylammonium
bicarbonate, 10 mM DTT v/v) was added to approximately 50 mg liver tissue and
homogenized using a bead homogenizer (Omni Bead Ruptor, Kennesaw, GA)19.
Samples were spun down at 1,000 x g for 5 min and the supernatant was collected. A
Pierce BCA protein assay kit (ThermoFisher Scientific, Waltham, MA) was used to
estimate protein concentration.

Lipid peroxidation and total cholesterol were

measured in human livers as previously described19.

A colorimetric assay kit

(Cayman Chemicals, Ann Arbor, MI) was used to measure triacylglycerides (TAG)
according to the manufacturer’s protocol.
4.3.6 In-solution trypsin digestion
Protein digestion was performed with slight modifications to the method
described by Jamwal et al.20. Samples (250 µg protein) were spiked with 2 ng BSA
and denatured with a DTT at a final concentration of 20 mM at 95˚C for 15 minutes in
a water bath shaking at 100 rpm. Samples were then alkylated using IAA (33mM) for
30 minutes at room temperature in the dark. Following alkylation, samples were
concentrated using ice-cold methanol, chloroform and water (2:1:1) to precipitate the
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proteins. Samples were spun at 10,000 x g for 5 minutes. The pellet was collected
and washed with ice-cold methanol. The remaining pellet was resuspended in 125 µl
of 50 mM ammonium bicarbonate (pH 7.8) containing 3% w/v DOC. TPCK-treated
trypsin was additionally added to the sample at a ratio of 1:20 (trypsin:protein).
Samples were transferred to PCT MicroTubes (Pressure Biosciences Inc., Easton,
MA) and the tubes were then placed in the NEP-Barocycler (Pressure Biosciences
Inc., Easton, MA) run at 35˚C for 75 cycles (50 sec at 25 kpsi, 10 sec at ambient
pressure). Subsequently, the same amount of trypsin was added again, and the samples
were placed back in the barocycler for the same cycle. After digestion, trypsin was
quenched, and DOC was precipitated by the addition of formic acid (5% in
acetonitrile) at a final concentration of 0.1%. Samples were spun at 10000 x g for 5
min at 10˚C and the supernatant was collected for LC-MS/MS analysis. Samples were
injected at a volume of 25 µL and analyzed using the LC-MS/MS method below.
4.3.7 LC-MS/MS analysis
Mass spectrometry was performed as described previously with slight
modifications19.

Data was collected on a SCIEX 5600 TripleTOF® mass

spectrometer using a DuoSpray™ ion source (SCIEX, Concord, Canada) coupled to
an Acquity UHPLC HClass system (Waters Corp., Milford, MA). An Acquity UPLC
Peptide BEH C18 (2.1 X 150 mm2, 300 Å, 1.7 µm) with an Acquity VanGuard precolumn (2.1 X 5 mm2, 300 Å, 1.7 µm) was used for sample separation. The column
was kept at 50˚C and the autosampler at 10˚C. A linear gradient run at 100 µL/min for
180-min was used to achieve separation.

Mobile phase A consisted of 99.9%

acetonitrile and 0.1% formic acid, and mobile phase B consisted of 99.9% water and

126

0.1% formic acid. The gradient was composed of 98% A from 0 to 5 min, 98% to
70% A from 5 to 155 min, 70% to 50% A from 155 to 160 min and 50% to 5% from
160 to 170 min. Mobile phase A was held at 5% from 170 to 175 min and the column
returned to starting conditions at 175 min and was held until the end of the run-in
order to equilibrate the column prior to the next sample.

Trypsin-digested β-

galactosidase peptides was used for mass calibration and monitoring of the QTOF
detector every 4 samples.
4.3.8 Mass spectrometer acquisition parameters
Positive ionization mode was used for both data-independent (SWATH –
Sequential Windowed Acquisition of all Theoretical Ions) and data-dependent
acquisition. The specific parameters were as follows: gas 1 55 psi, gas 2 60 psi,
curtain gas 25 psi, temperature 450˚C, ion spray voltage floating 5500 V, declustering
potential 100, collision energy 10 and collision energy spread 15.
For the data dependent acquisition, a maximum of 50 candidate ions were
monitored each survey scan. These ions had a charge state from 2 to 4. All ions that
fell between m/z 300-1250 and that were more intense than 25 cps were selected for
MS/MS analysis. Dynamic accumulation and a rolling collision energy based on each
ion’s m/z were used. A mass tolerance of 50 mDa was set during the initial survey
scan of 0.75 sec. The total cycle time was 3.50 sec.
The parameters used for SWATH-MS acquisition were the same as above
except for the following: temperature 400˚C and TOF masses were collected from m/z
300-1500. Seventy SWATH windows per cycles were collected over m/z 400-1100
with each window size being m/z 10. The total cycle time was 3.95 sec.
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4.3.9 Data processing
Data-dependent acquisition (DDA) samples were searched using Spectronaut
(Biognosys, Schlieren, Switzerland) against reviewed Swiss-Prot identifiers (October
2016). The Pulsar algorithm was used for identification of peptides and proteins from
both DDA and DIA data. BGS factory settings were used for the search. Tryptic
peptides were searched for with a minimum length of 7 amino acids and a maximum
of 52 amino acids with a maximum of 2 missed cleavages. All other options were
kept as the BGS factory settings. The spectral library generated from the DDA files
was used to then analyze the DIA files in Spectronaut. All settings in Spectronaut
were kept as the BGS factory settings except “PTM localization” and “used Biognosys
iRT kit” were unselected. Normalized intensity values were exported and converted
using excel.
4.3.10 Data normalization
The normalized output from Spectronaut were converted to picomoles per
gram of liver (pmol/g liver) by first using the Total Protein Approach (TPA) followed
by protein yield (protein per gram of liver or PPGL)21. The following equations
demonstrate how values were converted to their final form:

The natural log of the final values was taken, and statistical analysis was performed.
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4.3.11 Statistical analysis
Student’s t-test was used to determine the difference between NASH and
healthy groups.

Statistical values of p<0.05 were considered significant for the

analysis. SPSS 24 (IBM Corp., Armonk, NY) and Prism 6.0 (GraphPad Inc., La Jolla,
CA) were used to perform statistical tests and create graphs.

4.4 Results
A list of human proteins analyzed, and their orthologous mouse gene can be
found in Table 4.1.
4.4.1 Human liver histology
Criteria for the non NAFLD group of human livers included no level of
steatosis but some degree of lobular inflammation and hepatocyte ballooning and
fibrosis. For these samples specifically, only one sample had a degree of hepatocyte
ballooning, while about 50% had either low grade inflammation and/or fibrosis. In
order to allow this model to apply to the greatest population size possible, diabetes
status was disregarded. For the NASH group, steatosis levels ranged from 5% to
>67%. All samples had some degree of inflammation and hepatocyte ballooning
while most samples had low to mid-grade fibrosis. A full table of demographics can be
seen in Table 4.2.
4.4.2 Mouse liver histology
Mice in the healthy group were found to have no steatosis at week 18. Both
necrosis and inflammation were seen to be from 0-10% and no biliary hyperplasia was
seen. In the high fat diet group, lipid accumulation was seen to be >40% in all mice.
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Inflammation was seen to range from 0-25% and necrosis remained the same at 010%. Biliary hyperplasia increased from 0% to between 0 and 10%. ALIOS mice
additionally became less sensitive to glucose and insulin resistance compared to the
healthy mice indicating some level of diabetes. A full table of demographics can be
seen in Table 4.3.
4.4.3 Total protein extracted
Total protein extracted per gram of liver tissue was calculated in both species
and used to convert the units of protein expression. Between the high-fat and low-fat
mouse groups, no significant protein extraction differences were seen (154.4 ± 5.92 vs
162.4 ± 11.95 mg/g liver) whereas total liver weight was increased by about 140% in
the high fat group (3.052 ± 0.22 g vs 1.27 ± 0.02 g). Similar trends were seen in the
human group. The healthy group was able to extract 85.35 ± 3.0 mg/g liver where the
NASH group extracted 83.08 ± 4.7 mg/g liver. Total liver weight was also found to be
significantly increased from the healthy group to the NASH group (1.528 ± 60 g vs
1901 ± 97 g).
4.4.4 Effect of NASH on human drug metabolizing enzymes and transporters
CYP1A2 (p<0.01) and CYP2J2 (p<0.01) were all found to be significantly
downregulated in NASH samples compared to healthy samples. CYP2C8 and
CYP4A11 were also both found to be downregulated but were not significant.
UGT1A4 (p<0.05) and BSEP (p<0.05) were also both found to be significantly
decreased in the NASH group. Interestingly, UGT2A3 was found to be significantly
upregulated in the NASH group (p<0.05). The remainder of proteins remained similar
to the healthy group (Table 4.4). CYP3A4 levels were analyzed in samples that were
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free of phenytoin.

Prior to the phenytoin sample removal, CYP3A4 showed

significant decrease (p<0.01).
4.4.5 Effect of NASH on mouse drug metabolizing enzymes and transporters
Cyp1a2 (p<0.01), Cyp2c29 (p<0.001), Cyp2c37 (p<0.001), Cyp2j5 (p<0.05),
Cyp7b1 (p<0.05) and Cyp8b1 (p<0.05) were all found to be significantly
downregulated in the mice with NASH.

Cyp4a01 (p<0.05) was found to be

upregulated in the NASH group. Additionally, Ugt2a3 (p<0.05) and Bsep (p<0.05)
were both found to be significantly decreased in the NASH samples compared to
healthy. The remainder of the proteins remained similar to baseline (Table 4.5).
4.4.6 Comparison of species effect
The majority of drug disposition proteins analyzed showed similar trends when
comparing the mouse to the human liver samples. UGT2A3, CYP4A11 and CYP4A22
showed opposite trends in humans than mice. CYP2C8 and CYP2C9 showed much
greater and significant downregulation in mice than in human. The remaining proteins
showed the similar trends when comparing NASH to healthy samples in both species
(Table 4.6 and Figures 1-3).
4.5 Discussion
Mouse models are an important step in pre-clinical research. These models
can provide valuable information to assist with the validation that a drug has the
expected efficacy and safety profile that is necessary to move on to human studies.
Not only are mouse models important for new drug entities, they are also important in
understanding how the metabolic profile of a disease population will change. NAFLD
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is an ever-expanding field that new mouse models are being developed and validated
for.
There are numerous models of NAFLD that have been developed over the
years that incorporate genetics, diet and lifestyle or some combination of all three.
Some examples of these include the high fat/high cholesterol/high sugar diet (HF-HCHS), ob/ob mice, a methionine/choline deficient (MCD) diet, the Diet Induced Animal
Model of Non-Alcoholic Fatty Liver Disease (DIAMOND) and the ALIOS models.
While all these models lead to different characteristics of NASH, each one has their
pitfalls as it is with all animal models. The MCD diet is a nutrient deficiency model
where mice are fed high sucrose and low-fat food that is missing methionine and
choline. While this diet is able to achieve a NASH histology, the mice do not gain
weight or become insulin resistant22. Although the HF-HC-HS diet accurately achieves
all changes normally seen in NASH, it does not accurately represent a western culture
diet as the cholesterol content is significantly higher in the diet used for the model23.
The DIAMOND model uses a specific genetic mix between the 129S1/SvImJ
and the C57BL/6J strains of mice combined with a high fat diet and water with high
fructose/glucose in order to accurately develop NASH24. These results took 4 years to
obtain, though, and the results were not due to purely diet, but due to a genetic factor
as well as both parent strains did not have as pronounced NASH histology24. Another
model that does not have a dietary component is the ob/ob mouse model where there is
a loss of function mutation resulting in the gene that encodes for leptin causing it to
not work properly. As leptin acts to maintain homeostasis by reducing food intake,
this leads to severely obese mice. These mice show the traditional signs of being
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diabetic and can develop benign hepatic steatosis but do not progress into the NASH
territory25,26. Finally, another diet like DIAMOND is the ALIOS model. This uses a
realistic, high fat diet and water with high sugar content in order to simulate a western,
fast food diet along with a sedentary lifestyle.

These mice result in the NASH

phenotype after 16 weeks and show all components except for hepatocyte
ballooning16,27.
The ALIOS diet was chosen for this study as it is comparable to common
western diets and had no genetic factor introduced. The diet included a consumption
of sugar, cholesterol and saturated fats that is similar to eat fast food while also adding
sugar water to simulate soda consumption28-31. Additionally, the mice had a sedentary
lifestyle to help stimulate weight gain due to lack of exercise. This was done by
directly placing food in the cage, rather than in a top mounted feeder. Glucose and
insulin intolerance were noticed at 12 and 15 weeks, respectively. This means the
mice had reached diabetic conditions prior to sacrifice and their NASH diagnosis. It
has been shown that after 12 weeks on a supplemented cholesterol and 45% kcal diet
weight gain and insulin resistance develop but the addition of fructose is needed in
order to develop simple steatosis, NASH and even fibrosis16-18. Mells et al. found that
at 16 weeks, mild to moderate NASH had developed in aged mice32.
The majority of these models, mainly ob/ob and MCD, have been explored to
determine their effect on the mRNA, protein and enzymatic activity levels of drug
metabolizing enzymes expressed in the liver33. These results have not been consistent
as it is when studying human liver enzymes in NASH as well. The ALIOS model
currently has no literature reports on the effect on DME expression. It is additionally
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important to verify that the metabolic profile of the liver proteome remains consistent
between the mouse model and the human proteome that it is trying to mimic.
The ALIOS model shows good representation of the CYPs related to drug
metabolism. Both models show downregulation of CYP1A2 which has been reported
previously in human liver microsomes and hepatocytes34,35. The mouse model showed
significant downregulation in both CYP2C8 and CYP2C9 where the human samples
showed non-significant downregulation.

One literature report showed some

downregulation of CYP2C8 in NASH while no change in CYP2C9 while others report
no change in either enzyme36,37. The CYP2C family consists of 4 genes in humans
while there are 15 functional genes in mice. It is difficult to define orthologous genes
from human to mouse due to these differences as well as the sequence variation in
each38. It has been found that for both CYP2C8 and CYP2C9, the top 4 orthologous
mouse genes in sequence homology are Cyp2c29, Cyp2c37, Cyp2c38 and Cyp2c39
and they all match both human genes between 68 and 78%39. These difficulties could
explain the discrepancies that are being noted between the human and mouse models.
CYP27A1, CYP2D6 and CYP2E1 all showed no change in either model which is
consistent with literature except for CYP2E1 which has been reported to be
downregulated35,40,41. CYP2J2 showed downregulation in both species. This enzyme
is related to fatty acid synthesis but there is no current literature stating if there is any
change due to NASH. CYP4A11 is also involved with fatty acid metabolism as has
also been reported to be upregulated by NASH in mice42. While we show that
CYP4A11 is not changing in NASH, it has been previously reported that the
CYP4A11 gene is significantly increased in NAFLD livers43,44. This fluctuation in
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results between the species could be due to the lack of orthologous CYP4A family
proteins. CYP4A11 and CYP4A22 are closely related in humans with other forms
being seen in mice that make extrapolation and comparison difficult45. UGT1A6 and
UGT2A3 are responsible for the glucuronidation of numerous drugs, lipids and fatsoluble vitamins46,47. As humans have 1 copy of UGT1A6 while mice have 2 copies
of, Ugt1a6a and Ugt1a6b, this could explain the discrepancy between species in the
protein expression48. There are no reports as to the change of UGT2A3 in a mouse or
human model. The discrepancy seen between species could be due to the fact that the
UGT2 family enzymes have 70% sequence homology making it difficult to elucidate
orthologs46.
In human livers, in addition to what was visible in the mouse model. we have
seen progression of NAFLD lead to significant downregulation in CYP1A2,
CYP20A1,

CYP2E1,

CYP4F2,

and

CYP2J2.

CYP3A4

initially

shows

downregulation, but this can be attributed to the presence of the potent inducer,
phenytoin, being contained in some of these liver samples. We have also seen changes
in phase II metabolic enzymes including SULT1A1, SULT1C2, UGT1A3, UGT1A4,
UGT2A3 and transporters such as MDR1, BSEP and MRP3.
For this study, mice in the control group showed no signs of diabetes or high
NAS pathology. The healthy livers had no levels of steatosis while having low levels
of lobular inflammation and necrosis as can normally be found in human livers that
are not considered to have NAFLD49. By week 18 in the high fat diet group, mice
were seen to have developed symptoms of diabetes such as insulin resistance and
glucose intolerance. The mouse livers at this point were seen to have high levels of
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steatosis with all mice having >40% lipid accumulation while inflammation and
necrosis remained around similar levels. In order to properly match this model to
human data, our healthy group consisted of non-diabetic donors who had be scored
and determined to have no level of NAFLD. Donors with or without diabetes and
diagnosed NASH were used to match with the high fat diet mouse group. All human
fibrosis levels were considered, as fibrosis was not tested for in the mouse samples.
Interestingly, even though the total liver weight was significantly different between
groups in both species, the total protein yield remained similar between the groups.
This could be due to the changes in pathology throughout the liver. The section that
the pathologists examined may have had altered fat levels when compared to the
section that was used for protein measurement. It would be expected that protein yield
would decrease as fat content increased yet there is no strong correlation seen.
While other mouse models of NASH have reported combined effect of diet and
genetics on drug-metabolizing enzymes, no literature is currently available on how
these enzymes are changing in the ALIOS mouse model. Based on the current study,
the ALIOS diet model exhibits reasonable representation of changes in some of the
major phase I and phase II drug metabolizing enzymes as compared to human livers
from individuals with NASH. Importantly, CYPs that have orthologous mouse genes
such as CYP3A4 and CYP1A2 look similar in regard to disease progression in both
mice and human. Additionally, BSEP, an important bile acid transporter, seems to be
dysregulated in both models. The further development of mouse models is extremely
important in the advancement of drug and disease research and the ALIOS model
looks to be an accurate representation of major drug metabolism routes.
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4.7 Tables
Human gene
BSEP
CYP1A2
CYP27A1
CYP2C8
CYP2C9
CYP2D6
CYP2E1
CYP2J2
CYP3A4
CYP3A5
CYP4A11
CYP4A22
CYP7B1
CYP8B1
OATP1B1
SULT1A1
UGT1A1
UGT1A4

Mouse Gene
Bsep
Cyp1a2
Cyp27a1
Cyp2c29?
Cyp2c37?
Cyp2d9
Cyp2e1
Cyp2j5
Cyp3a11
Cyp3a13
Cyp4a10
Cyp4a12a
Cyp7b1
Cyp8b1
Slco1b2
Sult1a1
Ugt1a1
Ugt1a5
Ugt1a6a
Ugt1a6b
Ugt2a3
Ugt2b17

UGT1A6
UGT2A3
UGT2B17

Table 4.1. Comparison of human DME gene names and their orthologous gene in
mice.
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N
Age (y)
Female
Male
Caucasian
African American
Hispanic
Body weight (kg)
BMI (kg/m2)
Liver weight (g)
Malondialdehyde
(nmol/mg protein)
Cholesterol
(µg/g liver)
Triacyl glycerides (mg/g
liver)
PPGL (mg/g)
Non-diabetic
Diabetic
Steatosis
(0,1,2,3)

Lobular Inflammation
(0,1,2,3)
Hepatocyte Ballooning
(0,1,2,3)
Fibrosis
(0,1,2,3)

Human Control
42
46.5 (41.9 - 51.6)
16
26
33
8
1
83.5 (76.2 - 91.5)
29.3 (26.5 - 32.3)
1482.4
(1374.9 - 1598.3)

Human NASH
30
50.8 (47.3 - 54.5)
15
15
28
1
1
92.7 (86 - 99.9)
32.2 (29.9 - 34.7)
1839
(1678.4 - 2014.9) **

0.6 (0.5 - 0.7)

1.2 (1 - 1.6) **

14.2 (12.4 - 16.2)

20.8 (17.9 - 24.1) **

12.18 (10.01 - 14.82)

14.44 (12.1 - 17.23)

83.1 (77.4 - 89.3)
21
21
0 – 100%
1 – 0%
2 – 0%
3 – 0%
0 – 38%
1 – 52%
2 - 10%
3–0
0 – 98%
1 – 2%
2–0
0 – 50%
1 – 40%
2 – 7%
3 – 3%

79.8 (72.1 - 88.3)
13
17
0 – 0%
1 – 23.3%
2 – 33.3%
3 – 43.3%
0-0
1 – 77%
2 – 17%
3 – 6%
0–0
1 – 73%
2 – 27%
0 – 33.3%
1 – 53.3%
2 – 10%
3 – 3.3%

Table 4.2. Demographic characteristics of control and NASH groups. BMI: Bodymass index; PPGL: Protein per gram liver. P-value from non-parametric Mann
Whitney U test. * and ** represent p-value <0.05 and <0.01, respectively.
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N
Age (weeks)
Body weight (kg)
Liver weight (g)
PPGL (mg/g)

Steatosis
(0,1,2,3,4,5)

Necrosis
(0,1,2,3,4,5,)

Inflammation
(0,1,2,3,4,5)

Mouse LFD
5
18
35.55 ± 0.79
3.27 ± 0.02
162.4 ± 11.95
0 – 100%
1 – 0%
2 – 0%
3 – 0%
4 – 0%
5 – 0%
0 – 37.5%
1 – 62.5%
2 – 0%
3 – 0%
4 – 0%
5 – 0%
0 – 25%
1 – 75%
2 – 0%
3 – 0%
4 – 0%
5 – 0%

Mouse HFD
4
18
42.28 ± 0.81
3.05 ± 0.22**
154.4 ± 5.92
0 – 0%
1 – 0%
2 – 0%
3 – 0%
4 – 71.5%
5 – 28.5%
0 – 71.5%
1 – 28.5%
2 – 0%
3 – 0%
4 – 0%
5 – 0%
0 – 28.5%
1 – 57.2%
2 – 14.5%
3 – 0%
4 – 0%
5 – 0%

Table 4.3 Demographic characteristics of mouse low-fat diet (LFD) and high-fat
diet (HFD) groups. PPGL: Protein per gram liver. P-value from student’s t-test. **
represents p-value <0.01.
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Enzyme
BSEP
CYP1A2
CYP27A1
CYP2C8
CYP2C9
CYP2D6
CYP2E1
CYP2J2
CYP3A4
CYP3A5
CYP4A11
CYP4A22
CYP7B1
CYP8B1
OATP1B1
SULT1A1
UGT1A1
UGT1A4
UGT1A6
UGT2A3
UGT2B17

Healthy

NASH

22.87
(19.80-26.42)
275.0
(179.5-421.3)
264.9
(189.0-371.2)
350.2
(227.8-538.3)
908.2
(641.2-1287)
148.9
(106.0-209.1)
853.8
(661.7-1102)
43.60
(34.66-54.83)
434.1
(282.3-667.6)
56.63
(35.54-90.23)
403.0
(300.2-540.9)
58.75
(40.66-84.89)
17.96
(13.42-24.03)
254.3
(162.9-397.0)
68.27
(56.60-82.49)
883.8
(624.3-1251)
147.8
(104.4-209.2)
294.6
(212.8-407.8)
170.2
(121.5-238.5)
50.91
(40.70-63.66)
869.5
(607.6-1323)

18.20*
(15.42-21.47)
128.4*
(73.99-222.8)
262.4
(164.2-419.5)
309.6
(198.7-482.6)
629.4
(366.4-1081)
109.1
(68.39-174.0)
557.4
(337.4-920.9)
30.38
(22.20-41.59)
285.3
(199.6-407.7)
39.60
(25.42-61.71)
287.8
(169.5-488.8)
61.47
(42.09-89.76)
11.40
(7.499-17.33)
322.3
(234.3-443.2)
54.19
(38.13-77.01)
539.3
(298.9-973.2)
117.7
(72.53-190.9)
172.9
(108.6-275.4)
240.2
(165.9-347.8)
62.59
(43.31-90.46)
1104
(715.9-1703)

Fractional
Difference
-0.213
-0.485
0.166
-0.177
-0.171
-0.167
-0.084
-0.287
-0.325
-0.458
-0.147
-0.0488
-0.257
-0.025
-0.041
-0.14
-0.072
-0.287
0.441
0.309
0.140

Student’s t-test
p-value
0.039
0.027
0.978
0.215
0.091
0.265
0.099
0.057
0.132
0.280
0.231
0.866
0.065
0.421
0.210
0.124
0.427
0.053
0.171
0.307
0.475

Table 4.4 Effect of NASH on protein expression of various human DMES and
transporter proteins. Geometric mean and 95% confidence internal of protein
expression in pmol per g of liver tissue. P-value from independent Student’s t-test on
ln transformed data. * represents p-value <0.05.
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Enzyme
BSEP
CYP1A2
CYP27A1
CYP2C8
CYP2C9
CYP2D6
CYP2E1
CYP2J2
CYP3A4
CYP3A5
CYP4A11
CYP4A22
CYP7B1
CYP8B1
OATP1B1
SULT1A1
UGT1A1
UGT1A4
UGT1A6
UGT2A3
UGT2B17

Healthy

NASH

47.96
(40.68-56.55)
271.7
(203.7-362.6)
885
(700.5-1120)
1381
(1065-1790)
627.7
(508.0-775.6)
1141
(930.7-1399)
2258
(1757-2903)
236.2
(176.1-316.7)
644.7
(454.8-913.9)
155.5
(122.2-197.7)
531.4
(434.1-650.4)
334.8
(279.4-401.1)
166.4
(110.2-251.2)
260.2
(195.9-345.5)
289.5
(213.8-392.0)
1759
(1352-2289)
629.7
(528.5-750.3)
207.3
(164.1-261.8)
3314
(2759-3981)
930.9
(749.2-1157)
3371
(2618-4340)

35.07*
(26.97-45.60)
118.2**
(58.69-238.1)
771.6
(652.5-912.3)
363.0***
(126.6-403.7)
226.1***
(126.6-403.7)
921.6
(597.4-1422)
2368
(2068-2711)
147.4*
(86.41-251.5)
624.7
(475.5-820.7)
117.1
(70.78-193.6)
741.8*
(517.7-1063)
399.3
(260.0-613.1)
78.82
(15.18-409.4)
168.2*
(102.5-275.8)
257.0
(191.6-344.8)
1425
(1154-1760)
649.1
(499.6-843.4)
184.9
(131.6-259.8)
3252
(3056-3461)
711.0*
(576.2-877.3)
2907
(2623-3221)

Fractional
Difference
-0.266
-0.544
-0.137
-0.721
-0.626
-0.179
0.034
-0.363
-0.052
-0.229
0.409
0.213
-0.472
-0.344
-0.122
-0.199
0.033
-0.106
-0.026
-0.241
-0.150

Student’s t-test
p-value
0.015
0.008
0.236
<0.001
<0.001
0.186
0.677
0.042
0.851
0.139
0.036
0.247
0.072
0.045
0.448
0.129
0.774
0.422
0.813
0.038
0.209

Table 4.5. Effect of NASH on protein expression of various mouse orthologs of
DMEs and transporter proteins. Geometric mean and 95% confidence internal of
protein expression in pmol per g of liver tissue. P-value from independent Student’s ttest on ln transformed data. * represents p-value <0.05.
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Comparison of ratio differences
Enzyme

Human

Mouse

Human/Mouse
trend

-0.213

-0.266

↓↓/↓↓

-0.485

-0.544

↓↓/↓↓

0.166

-0.137

↔/↔

-0.177

-0.721

↔/↓↓

-0.171

-0.626

↔/↓↓

-0.167

-0.179

↔/↔

-0.084

0.034

↔/↔

-0.287

-0.363

↓/↓↓

-0.325

-0.052

↔/↔

-0.458

-0.229

↔/↔

-0.147

0.409

↔/↑↑

-0.0488

0.213

↔/↑

-0.257

-0.472

↓/↓

-0.025

-0.344

↔/↓↓

-0.041

-0.122

↔/↔

-0.14

-0.199

↓/↓

-0.072

0.033

↔/↔

-0.287

-0.106

↓/↓

0.441

-0.026

↑/↔

0.309

-0.241

↑/↓↓

0.140

-0.150

↑/↓

BSEP
CYP1A2
CYP27A1
CYP2C8
CYP2C9
CYP2D6
CYP2E1
CYP2J2
CYP3A4
CYP3A5
CYP4A11
CYP4A22
CYP7B1
CYP8B1
OATP1B1
SULT1A1
UGT1A1
UGT1A4
UGT1A6
UGT2A3
UGT2B17

Table 4.6. Comparison of alteration to DMEs and transporters in mouse and
human livers. Values presented are fractional differences between healthy and NASH
samples in both species. ↓↓ and ↑↑ represent p<0.05, ↓ and ↑ represent a nonsignificant trend and ↔ represents no change.
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4.8 Figures

Figure 4.1 Effect of NASH on protein expression of various CYP450 proteins in
human and mice. Graphs represent ratio of NASH mean protein expression to healthy
mean protein expression. Student’s t-test was used to test for significance between
NASH and healthy groups in each species. *, ** and *** represent p-value <0.05,
<0.01 and <0.001, respectively
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Figure 4.2. Effect of NASH on protein expression of various CYP450 proteins in
human and mice. Graphs represent ratio of NASH mean protein expression to healthy
mean protein expression. Student’s t-test was used to test for significance between
NASH and healthy groups in each species. *, ** and *** represent p-value <0.05,
<0.01 and <0.001, respectively
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Figure 4.3 Effect of NASH on protein expression of various UGT and drug
transporter proteins in human and mice. Graphs represent ratio of NASH mean
protein expression to healthy mean protein expression. Student’s t-test was used to test
for significance between NASH and healthy groups in each species. *, ** and ***
represent p-value <0.05, <0.01 and <0.001, respectively
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CONCLUSION
This works demonstrates the alterations found in drug disposition proteins in
cases of both NAFLD and diabetes. This first part of this dissertation put the
methodology in place to accurately analyze the effect of these diseases. Drug
transporters are low abundant membrane proteins and therefore traditionally hard to
accurately measure. The methodology developed allowed for the quantification of 13
clinically relevant drug transporters that accurately matched literature values. This
method was able to additionally be applied to the measurement of phase I and II
DMEs. Additionally, the first part showed how enzyme inducing medications, such as
phenytoin, remain in the liver after is has been donated to science. As a result, certain
medications can significantly alter a metabolic profile as it was seen with the induction
of CYP3A4.
With the knowledge gained in part I of this manuscript, part II was then able to
accurately measure DMEs and transporters and assess the validity of an American
diet-based mouse model. It was seen that numerous phase I and II metabolic enzymes
were significantly changing across both NAFLD and diabetes and in some cases, the
effect was most likely being exacerbated by both diseases. This is of large concern as
patients with NAFLD and diabetes generally have numerous other health conditions
that they are being treated for. This indicates that they would be taking numerous
medications that have the potential to be altered by the noted effect on the enzymes.
These results translated nicely to the mouse model which showed that most
drug metabolizing CYPs were altered in the same direction across species. Although
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some of the phase II metabolic enzymes were seen to be differentially changing, this
can be explained by the differences in the mouse genome and the difficulty in the
measurement of certain proteins. This mouse model is able to represent the realistic
changes occurring due to the NAFLD being induced by diet and lifestyle and not
genetics. There are no mouse models that will accurately predict all factors of a given
disease, but the ALIOS model looks to accurately represent the phase I drug
disposition profile of a human with NAFLD and/or diabetes.
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